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ABSTRACT 
The secretory pathway of a eukaryotic cell exerts a stringently regulated quality control 
system for the correct folding and transport of newly synthesised proteins and their 
subsequent transfer to their final destinations. While this pathway has been mostly studied in 
yeast, it has become increasingly clear that aberrations in its function are the main causes of a 
range of human disorders, and we are still in the process of gathering knowledge of the 
underlying molecular structures and mechanisms of the disease-causing agents in order to 
fully understand their impact. ERGIC-53, Erv41p and Ktr4p are all membrane anchored 
proteins involved in the transport or processing of glycoproteins, and form the main focus of 
this thesis. We have used X-ray crystallography and small-angle X-ray scattering, together 
with complementary biophysical and biochemical methods, to provide detailed descriptions 
of these proteins.  
The human glycoprotein transporter ERGIC-53 is responsible for the export of specific cargo 
proteins, which it binds in the endoplasmic reticulum (ER) and releases in the ER-Golgi 
intermediate compartment whilst cycling between the two organelles. Association of  
ERGIC-53 with the co-transporter MCFD2 is required for the transport of a subset of cargo 
proteins. ERGIC-53 is only able exert its function when present within the cell as a hexamer, 
but the details regulating its oligomeric state are still debated, and the structure of the 
hexameric protein remains unknown. We show that the oligomerisation of ERGIC-53 is 
independent of disulfide-bond formation and, based on small-angle X-ray scattering 
experiments, propose two alternative shapes describing the structure of the soluble lumenal 
part of the protein in its hexameric state. 
Erv41p is a glycoprotein transporter found in complex with its homologue Erv46p in yeast, 
and, similarly to ERGIC-53, the complex governs the export of cargo proteins from the ER to 
the Golgi apparatus, as well as the retrieval of escaped proteins back towards the ER. We 
have determined the structure of the soluble domain of Erv41p by X-ray crystallography, and 
show that the protein is comprised of a twisted β-sandwich. With almost the entirety of the 
concave face of Erv41p being negatively charged, this could be the site of interaction with its 
cargo or another interaction partner. 
One cargo protein that has recently been revealed to be transported by the Erv41p/Erv46p-
complex is Ktr4p, a protein localised to the Golgi apparatus. Ktr4p is a member of a protein 
family associated with glycoprotein processing. The structures of the Ktr4p apo-protein and 
its complex with GDP were determined by X-ray crystallography and show that the protein is 
comprised of a central β-sheet surrounded by α-helices, and that it belongs to the GT-A fold 
class of glycosyltransferases In addition, we have biochemically characterised the protein's 
function and show that it indeed possesses mannosyltransferase activity.  
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1 INTRODUCTION 
1.1 GENERAL INTRODUCTION 
In the evolution from the prokaryotic to the eukaryotic cell, several instrumental aspects of 
life changed fundamentally, and one of the most important was the development of 
specialized organelles that perform dedicated functions within the cell. These physiologically 
separated compartments, each surrounded by semi-permeable membranes that allow 
communication between the cytosol and the organelles, as well as direct communication 
between the different organelles, provide an increased level of order in the eukaryotic cell and 
give it the capacity to perform a range of complex cellular processes simultaneously. 
The nucleus was the first organelle to be discovered, having been first observed by Antonie 
van Leeuwenhoek (1632 – 1723) in 1719, but it was only in the early 20th century, with the 
advent of our understanding of chromosomes and heredity, that its function became clear. 
Around the same time, in 1910, Camillo Golgi first observed what he termed the internal 
reticular apparatus under a light microscope. This organelle, which is now commonly 
referred to as the Golgi apparatus, is usually located close to the nucleus and in most 
eukaryotes it consists of several cisternae, a network of connected, membrane-enclosed 
compartments which appear as flattened disks in electron micrographs. The Endoplasmic 
Reticulum was not identified until much later, after development of the first electron 
microscopes. In 1945, Keith R. Porter, Albert Claude, Brody Meskers and Ernest R. Fullam, 
using a magnification of 1600x, first observed a network of membranes between the nucleus 
and the Golgi apparatus, which they termed reticulum, and which is now known as the 
Endoplasmic Reticulum. 
These three organelles have been studied and characterised extensively since their respective 
discoveries, and an intricate functional and physical connectivity between them has become 
evident. Together, they not only govern the correct folding of proteins by providing a suitable 
environment, but also provide crucial enzymes regulating post-translational modifications, 
and a means of transporting the newly synthesised proteins to their final destinations. This 
organised system for the maturation, sorting and transport of newly-synthesised proteins is 
known as the secretory pathway. 
The importance of the secretory pathway in the human cell is emphasised by the fact that 
several diseases are associated with failures in the folding and transport of proteins, such as 
different types of cancers and combined deficiency of blood coagulation factors V and VIII. 
Research conducted in the past few decades has significantly improved our understanding of 
the molecular mechanisms causing these diseases. However, in order to pinpoint the exact 
root of the aberrant molecular behaviour, every step of the pathway, and in particular each of 
the disease-causing proteins, must be studied in detail at the molecular level. 
In this thesis we have applied X-ray crystallography together with biochemical and 
biophysical methods to characterise several different proteins involved in protein transport in 
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the early secretory pathway: ERGIC-53 is, together with its interaction partner MCFD2, 
responsible for the secretion of the blood clotting proteins factor V and VIII, and a number of 
other proteins. Erv41p has been shown to travel from the ER to the Golgi in vesicles, and has 
also been implicated in protein transport. Lastly, Ktr4p is involved in the glycosylation of 
secreted proteins. With these studies we hope to have provided new insights into the 
structures and functions of the proteins themselves, but also to have contributed towards a 
greater understanding of protein transport in the early secretory pathway. 
 
1.2 THE EARLY SECRETORY PATHWAY 
The secretory pathway – sometimes also called the exocytotic pathway - consists of several 
physiologically separated compartments, each of which provides a unique environment that is 
required for the correct folding, sorting, and post-translational modification of a newly 
synthesised protein. Recent estimates show that about a third of all synthesised proteins travel 
through the secretory pathway (Stolz & Wolf, 2010), and these are collectively referred to as 
secretory cargo proteins. After synthesis of the proteins on the surface of the ER, they are 
folded, receive post-translational modifications, and are sorted into different compartments. 
 
Figure 1: A schematic representation of the components of the secretory pathway. 1: Nucleus, 2: rough ER, 3: 
smooth ER, 4: ER exit sites; 5: COPII-coated vesicle, 6: COPI-coated vesicle, 7: ERGIC, 8: cis-Golgi network, 
9: median Golgi-network, 10: trans-Golgi network, 11: endosome, 12: lysosome, 13: clathrin-coated vesicle 
14: extracellular space 
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While some proteins reside in the ER, others exit it in vesicles and commence an anterograde 
journey along the secretory pathway towards the ER-Golgi Intermediate Compartment 
(ERGIC), the Golgi apparatus and ultimately lysosomes or secretory vesicles leading to the 
plasma membrane or the extracellular space (figure 1). The transport of proteins between the 
different organelles of the secretory pathway is directed by vesicles that bud off from the 
membrane loaded with cargo molecules and travel towards the target compartment, where, 
after fusion of the vesicle with the target membrane, the cargo is released. The formation and 
directionality of the vesicles is mediated by their coat proteins: COPI, COPII and clathrin 
each are responsible for the sorting of vesicles at various stages of the secretory pathway. The 
secretory pathway is directly linked to the endocytotic pathway, which allows for protein and 
nutrient uptake into the cell via endosomes budding from the plasma membrane.  
The secretory pathway is a very dynamic system which is able to respond to the varying tasks 
posed to cells in different environments and, as such, it has the capability of rapidly 
increasing or decreasing the protein turnover according to the cell’s demands (Kondylis et al., 
2009).  
 
1.2.1 The Endoplasmic Reticulum 
The endoplasmic reticulum was first observed in 1945, as the advancement of the electron 
microscope allowed for greater sample magnifications, and it was described as a “lace-like 
reticulum” by Porter et al. (Porter et al., 1945). Later, this structure was termed the 
endoplasmic reticulum, a term derived from the words endon (gr. ἔνδον, inner, within), 
plasma (gr. Πλάσµα, something formed) and reticulum (lat. network). Since its discovery, the 
ER has been studied in detail and observed in almost every cell type, although it is notably 
absent in erythrocytes and spermatozoa. In cell types with a high protein turnover, such as 
pancreatic exocrine cells, the ER can take up a major portion of the cells volume. 
Functionally, the ER is responsible for folding of secretory proteins, quality control and post-
translational modifications, as well as protein sorting. In addition, it is the organelle where the 
synthesis of fatty acids, the major components of membranes, and steroid hormones takes 
place. Furthermore, the ER acts as a storage compartment for calcium ions, which serve a 
central function in signal transduction. The free Ca2+ concentration in the ER has been 
measured at 0.5 – 1 mM, with another 1 – 5 mM bound to proteins (Bygrave & Benedetti, 
1996), compared to nanomolar concentrations in the cytosol. In this sense, the ER is therefore 
topologically similar to the extracellular space, where the free Ca2+ concentration is in the 
low millimolar range (Clapham, 2007). 
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1.2.2 The ER-Golgi Intermediate Compartment 
As its name implies, the ER-Golgi intermediate compartment (ERGIC) is situated between 
the ER and Golgi apparatus. It is a highly dynamic cluster of vesicles emerging from the ER 
and assembling into loosely connected tubular structures, and is therefore also referred to as 
vesiculotubular clusters (VTC). First described in 1984 (Saraste & Kuismanen, 1984), its 
existence was debated until a specific marker for the ERGIC was discovered in 1988 
(Schweizer et al., 1988). The presence of this marker, a protein called p53, was later also 
confirmed by the identification of its rat homologue, now called p58/ERGIC-53 (Saraste et 
al., 1987; Lahtinen et al., 1992). Today, the ERGIC is recognised as a stationary site for the 
anterograde and retrograde sorting of proteins in ER-to-Golgi traffic (Appenzeller-Herzog & 
Hauri, 2006) and has been shown to differ biochemically from both the ER and the Golgi 
apparatus, specifically in its pH and calcium concentration. While the exact pH value of the 
ERGIC has so far not been determined, it is estimated to lie between the values encountered 
within the ER (pH 7.1 – 7.4) and the Golgi apparatus (pH 5.9 – 6.3) (Paroutis et al., 2004). 
The linear decrease of the pH value from the ER to the Golgi apparatus stands in contrast 
with the calcium concentration in each compartment. The calcium concentrations within both 
the ER and Golgi apparatus have been determined to be relatively high (0.5 – 1 mM), 
whereas the concentration within the ERGIC was below the detection limit (Pezzati et al., 
1997). It is now believed that these physiological differences along the early secretory 
pathway provide a means for the sorting of proteins for onward transport towards the Golgi 
apparatus or retrieval back towards the ER. 
 
1.2.3 The Golgi Apparatus 
Camillo Golgi was the first to observe a basket-like network surrounding the nucleus in 
Purkinje cells in 1898 and he called it the “apparato reticolare interno”, or internal reticular 
apparatus. Today, this organelle is referred to as the Golgi apparatus. Until the 1960's, his 
description of the Golgi apparatus remained heavily debated, and the function of the proposed 
organelle remained obscure. As was the case with the discovery of the ER, it was the 
development of electron microscopy methods, together with autoradiography, which put the 
debate to rest. The Golgi apparatus serves two basic functions: it is the host organelle for 
further glycosylation of proteins, and it serves as another sorting hub for proteins travelling 
along the secretory pathway, directing them either along the anterograde direction towards 
the plasma membrane, or along the retrograde pathway back towards the ER. The Golgi is 
comprised of several tightly stacked cisternae which have an inherent directionality, the cis-
side which faces the ER and transiently fuses with vesicles arriving from the ERGIC, the 
medial Golgi, and the trans-side which faces the plasma membrane. It is not a stable 
organelle, but rather exhibits a continuous flux of protein-loaded vesicles from the cis-Golgi 
network (CGN) towards the trans-Golgi network (TGN). The exact manner in which proteins 
traverse the cisternae, be it vesicular transport, percolation, or cisternal progression, is to this 
day still controversial (Pelham & Rothman, 2000; Patterson et al., 2008). In addition to 
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anterograde and retrograde protein sorting, the Golgi apparatus is responsible for O-linked 
glycosylation and extensive remodelling of the branched N-linked glycan, which proteins 
receive in the ER. The complexity and diversity of the final products are vast; the glycans are 
often branched and can be comprised of more than 200 sugar molecules, which, in addition, 
are potentially modified with phosphate, sulfate, acetate, or phosphorylcholine (Stanley, 
2011). Finally, after this extensive posttranslational processing, secretory proteins exit the 
Golgi at the TGN and continue their journey to their final destinations. 
 
1.3 PROTEIN TRANSLATION, FOLDING AND SORTING 
All nascent proteins destined to enter the secretory pathway are guided towards the ER via a 
16-30 amino acid long signal sequence at their N-terminus (Blobel & Dobberstein, 1975). 
This sequence often contains a stretch of hydrophobic amino acids in its centre which, during 
its synthesis, is recognised by the signal recognition particle (SRP), a ribonucleoprotein, 
leading the translating ribosome to the SRP-receptor located on the surface of the rough 
endoplasmic reticulum (Akopian et al., 2013). The signal peptide is subsequently translocated 
into the ER membrane through a complex of proteins, which is generally referred to as the 
translocon (Denks et al., 2014).  
Within the ER lumen, the hydrophobic regions of the nascent peptide are often recognised 
and bound by proteins of the hsp70 and hsp40 families, which help to prevent the growing 
protein chain from uncontrolled aggregation and instead assist in protein folding (Ellgaard & 
Helenius, 2003). Additionally, the branched core oligosaccharide GlcNAc2Man9Glu3 is 
covalently attached to the majority of proteins at asparagine residues within the consensus 
sequence -NXS/T-, where X is any amino acid except proline (Gavel & von Heijne, 1990). 
This reaction is performed by a membrane protein complex called oligosaccharyltransferase 
(OST) (Mohorko et al., 2011), and the attachment of the branched glycan also helps prevent 
aggregation of the folding-intermediates. The glycan furthermore acts as a maturation signal 
during the ensuing cyclic folding process. The glucosidases I and II sequentially trim the 
oligosaccharide of its terminal glucose moieties, producing GlcNAc2Man9Glu1 (Grinna & 
Robbins, 1980), which is a substrate for the transmembrane protein calnexin (CNX) and its 
soluble paralog calreticulin (CRT) (Helenius et al., 1997). The folding intermediates also 
associate with the protein disulfide-isomerase Erp57, which aids in the formation of 
intramolecular disulfide bonds, via calnexin and calreticulin. During multiple rounds of 
association and dissociation from calnexin and calreticulin, the protein undergoes attempts to 
fold into its native structure and if the process succeeds, glucosidase II removes the last of the 
three glucose moieties, which allows the folded protein to exit the ER. In contrast, non-
natively folded proteins are recognised and re-glucosylated by the UDP-glucose:glycoprotein 
glycosyltransferase (UGGT), which again allows interaction with calnexin/calreticulin 
(Parodi, 2000). This cycle continues until the protein succeeds in achieving its native state, or, 
if it fails to do so, is targeted for ER-associated degradation.  
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Figure 2: Schematic overview of the glycoprotein folding pathway. For clarity, calnexin has been omitted from 
the figure. 
 
In this process, α-1,2-mannosidase I removes one terminal mannose moiety from the 
branched oligosaccharide, producing GlcNAc2Man8 (Tremblay & Herscovics, 1999), which  
interacts with the ER-degradation-enhacing 1,2-mannosidase (EDEM) (Kanehara et al., 
2007). This enzyme is thought to remove the terminally misfolded protein from the 
calnexin/calreticulin cycle and to direct it, with the help of XTP-3B, OS-9, Sel1L and Hrd1, 
towards the retrotranslocation channel (Gauss et al., 2011). The retrotranslocation channel 
exports the protein through the ER membrane into the cytosol, where it is poly-
ubiquitinylated and degraded by the proteasome (figure 2). The process of ER associated 
degradation (ERAD) is still very poorly understood, and the nature of the retrotranslocation 
channel is heavily debated (Nakatsukasa & Brodsky, 2008; Hampton & Sommer, 2012). 
Overall, these complex processes protect the cell from accumulating misfolded and 
dysfunctional proteins. 
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1.3.1 Protein Exit from the ER along the Secretory Pathway 
After the functional integrity of a newly synthesised protein is established, it is sorted from 
ER resident proteins and moved to ER exit sites (ERES) (Budnik & Stephens, 2009), which 
are highly curved parts of the smooth ER (Okamoto et al., 2012). Even though the ERES are 
clearly distinguishable on electron micrographs (Bannykh et al., 1996), it remains unknown 
how their composition differs from other parts of the ER. The distinction of the ERES from 
the rest of the ER, however, serves a crucial function in protein sorting. This distinction may 
be established by the retention of incorrectly folded proteins to other sites of the ER via their 
binding to chaperones. Additionally, numerous cargo receptors, responsible for the 
recognition and transport of proteins approved for ER exit, are present at the ER exit sites, 
and they might provide another selective barrier for the ER exit of folding-intermediates by 
being incapable of binding proteins that are unfit for release. A third mechanism to uphold 
the integrity of the secretory pathway might be the prevention of protein aggregates being 
packed into budding vesicles. The vesicles are typically only ~50 nm in diameter, which 
would likely inhibit the exit of very large protein aggregates from the ER. 
Following their localisation to the ERES, secretory proteins are packed into COPII-coated 
vesicles. The COPII-coat (COP refers to the coat protein complex) consists of an inner layer, 
which is  comprised of the Sec23-Sec24 heterodimer, recruited to the ER-membrane by the 
small GTPase Sar1, and an outer layer, comprised of the heterotrimeric Sec13-Sec31 
complex (Jensen & Schekman, 2011). The fission of the COPII-coated extrusion from the 
ER-membrane to form an intact vesicle appears to be governed by the Sec13-Sec31 complex 
(Matsuoka et al., 1998). At the target membrane, the force enabling the fusion of the vesicle 
with the membrane is exerted by SNARE and SM (Sec1/Munc18-like) proteins (Südhof & 
Rothman, 2009). 
 
1.3.2 Protein Sorting 
The balance between anterograde and retrograde vesicle traffic maintains the integrity of the 
different organelles in the early secretory pathway both by keeping the membranes of the 
organelles intact, as well as by retrieving proteins that have escaped from the ER. While 
anterograde vesicle traffic is governed by COPII-coated vesicles, retrograde traffic is 
maintained by COPI-coated vesicles. Soluble ER-resident proteins generally contain a C-
terminal ER-retention signal (KDEL in humans, HDEL in yeast), and, via the interaction of 
the signals with the COPI-associated KDEL-receptors, are retrotranslocated towards the ER 
in the case of escape (Munro & Pelham, 1987; Pelham et al., 1988). The transport of 
membrane-anchored proteins is guided by their N- or C-terminal sorting sequences; a di-basic 
(KK, RR) motif interacts directly with COPI and is thereby retrieved to the ER (Jackson et 
al., 1990), while proteins containing a more diverse di-acidic (e.g. YENE, DID) or di-
hydrophobic (e.g. FF, LL, YL, FY) motif are sorted to the ERGIC and Golgi apparatus via 
COPII vesicles (Barlowe, 2003). 
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1.4 TRANSPORT RECEPTORS AND THEIR CARGO 
The active shuttling of soluble proteins within COP-coated vesicles requires the mediation of 
the interaction of the cargo to the COP-coat via transmembrane receptors. A growing number 
of these transport receptors, as well as their specific cargo molecules, have been identified 
over the course of the last two decades (table 1), but their cargo recognition processes remain 
poorly understood in many cases. Most of the early work on the identification and cargo 
specificity of transport proteins was performed in the yeast S. cerevisiae, and major 
contributions to this research area are provided by the work performed in the laboratories of 
C. Barlowe and H.-P. Hauri. 
Receptor Species Cargo Reference 
Multispanning transmembrane receptors 
Erv29p yeast gpαf, CPY, PrA (Belden & Barlowe, 2001; 
Caldwell et al., 2001; Otte & 
Barlowe, 2004) 
Erv26p yeast P-ALP, Ktr3p (Bue et al., 2006; Bue & Barlowe, 
2009) 
Erv14p yeast Axl2p, Sma2p (Powers & Barlowe, 2002; 
Nakanishi et al., 2007) 
KDEL receptor mammals -KDEL sequence (Munro & Pelham, 1987) 
Protein cornichon homolog 4 mammals GPCR (Sauvageau et al., 2014) 
p24 proteins 
Emp24p-Erv25p yeast Gas1p, Suc2p (Muñiz et al., 2000) 
ER vesicle proteins 
Erv41p/Erv46p yeast Ktr4p, Gls1, Fpr2 (Noda et al., 2014; Shibuya et al., 
2015) 
ERGIC1/ERGIC2/ERGIC3 mammals unknown  
L-type lectins 
Emp46p/Emp47p yeast Ssp120 (Margulis et al., 2015) 
ERGIC-53/MCFD2 mammals FV, FVIII, catC, catZ, 
A1AT, IgM, Mac2-bp, 
nicastrin, FGFR3, 
SUMF1 
see text 
ERGL mammals unknown  
VIP-36 mammals unknown  
VIPL mammals unknown  
Table 1: Protein sorting receptors of the early secretory pathway and their cargo proteins. 
 
One of the first transport receptors to be identified in yeast was the conserved, multispanning 
transmembrane receptor Erv29p, which has been isolated from COPII-coated vesicles and 
found to be directly required for the export of a number of cargo proteins from the ER to the 
Golgi apparatus (Belden & Barlowe, 2001). Following this discovery, Erv26p and Erv14p 
were identified. Erv26p is non-essential, but it has been found to cycle between the ER and 
the Golgi apparatus and to interact with the proteins of the COPI-complex (Bue & Barlowe, 
2009). Similarly, Erv14p has been shown to cycle between the ER and Golgi, but this protein 
is involved in the packaging of cargo into COPII-coated vsicles (Powers & Barlowe, 2002). 
The members of the p24 protein family are type I membrane proteins with a lumenal GOLD 
(Golgi dynamics) domain, a transmembrane helix and C-terminal tail containing binding 
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motifs to COPI and COPII proteins (Fiedler et al., 1996). They are highly conserved from 
yeast to mammals and were first identified as abundant constituents of COPI and COPII-
coated vesicles (Stamnes et al., 1995), and shortly after their discovery their role in protein 
transport and sorting was established (Schimmöller et al., 1995). As a knock-out of all eight 
family members in the yeast S. cerevisiae showed no visible difference in protein transport 
(Springer et al., 2000), the precise role of these proteins remained puzzling for a substantial 
period of time and it was only more than a decade after their discovery that their function as 
receptors for glycophosphatidylinositol (GPI)-anchored proteins was revealed (Takida et al., 
2008). 
In humans, the ERGIC family is comprised of four members, namely ERGIC-53, ERGL 
(ERGIC-53 like), VIP-36 and VIPL (VIP-36 like). All four members of the family are type I 
transmembrane proteins comprised of an N-terminal lumenal part, one transmembrane helix 
and a short, C-terminal tail exposed to the cytoplasm. On the lumenal side they all contain a 
carbohydrate recognition domain (CRD) belonging to the class of L-type lectins, which is 
defined by the structural similarities and the glycan-binding abilities of its members. 
Structurally, the CRD consists of a β-sandwich structure with a concave and a convex sheet, 
and two conserved metal-ion binding sites proximal to the carbohydrate binding site. The 
members of this family of L-type lectins bind their cargo proteins by recognising high-
mannose carbohydrates, but in some cases via protein-protein interactions as well 
(Appenzeller et al., 1999; Carrière et al., 1999; Satoh et al., 2007).  
 
1.4.1 ERGIC-53 
In 1988, Schweizer et al. produced an antibody with the goal of specifically labelling a 
tubulovesicular compartment near the cis side of the Golgi apparatus of a human intestinal 
cell line, and were able to show that this monoclonal antibody bound to a specific membrane 
protein of 53 kDa (Schweizer et al., 1988). Independently, Saraste and co-workers identified 
a protein of 58 kDa by a similar approach, namely by the generation of polyclonal antibodies 
against a fraction of the Golgi apparatus of rat pancreas cells (Saraste et al., 1987). 
Furthermore, a third group isolated an intracellular protein in search for lectins by mannose-
column chromatography (Pimpaneau et al., 1991). It was later revealed that these three newly 
identified proteins were in fact the same protein, which is now termed ERGIC-53 or, less 
commonly, LMAN1 (Arar et al., 1995; Itin et al., 1996).  
The discovery of ERGIC-53 was therefore a key factor for the identification of the ER-Golgi 
intermediate compartment (ERGIC), and this is where it is most abundant. It is also found, 
albeit in lower abundance, at ER exit sites (ERES) and in the first cis-cisternae of the Golgi 
apparatus (Schweizer et al., 1988; Chavrier et al., 1990; Klumperman et al., 1998), where it 
is associated with COPII and COPI proteins (Tisdale et al., 1997; Wendeler et al., 2007). 
Since its discovery, ERGIC-53 has been extensively used to study the transport routes of the 
early secretory pathway.  
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ERGIC-53 is now known to be a non-glycosylated type I integral membrane protein, which 
assembles into homodimers and homohexamers immediately after its synthesis (Schweizer et 
al., 1988; Lahtinen et al., 1992). Sequence comparisons have revealed that it contains a 
lumenal domain resembling the carbohydrate recognition domain (CRD) of plant leguminous 
lectins (Fiedler & Simons, 1994) at its N-terminus. An oligomerisation domain is located to 
the C-terminus of the CRD, and this has been proposed to be instrumental for the 
oligomerisation of the protein (Lahtinen et al., 1999; Zhang et al., 2006; Zheng et al., 2010). 
The oligomerisation domain is followed by a short linker, connecting the protein to the ER 
membrane, which contains two cysteine residues (Cys-466 and Cys-475). On its cytosolic 
side, a short tail with the very C-terminal KKFF motif contains information for the recycling 
of the protein. 
The CRD is the best characterised part of ERGIC-53, and its modes of carbohydrate 
recognition and release are well understood. After the first crystal structure of the CRD from 
the rat protein had been determined (Velloso et al., 2002), it became clear that the domain 
contains two Ca2+-binding sites (Velloso et al., 2003) and a large carbohydrate binding site 
able to accommodate complex glycans (Zheng et al., 2013; Satoh et al., 2014). It was 
therefore hypothesised that ERGIC-53 functions as a glycoprotein receptor involved in the 
export of glycoproteins from the ER. The discovery that the correct localisation of the thiol-
proteases Cathepsin C and Cathepsin Z to the lysosomes depends on ERGIC-53 
(Vollenweider et al., 1998) further strengthened the hypothesis. Since then, an additional, 
albeit small, number of proteins dependent on ERGIC-53 for their ER export have been 
identified. Most prominently, the blood coagulation factors FV and FVIII rely on ERGIC-53 
for their secretion from the cell (Nichols et al., 1998), and a disruption of their interaction 
with the transport receptor leads to the bleeding disorder F5F8D (combined deficiency of 
factors FV and FVIII). Patients suffering from this disorder exhibit a concentration of the 
blood coagulation factors in the blood stream that is only 5 – 30% of the level in healthy 
patients. The other, thus far identified, cargo proteins of ERGIC-53 are the serine protease 
inhibitor α1-antitrypsin (Nyfeler et al., 2008b), the antibody IgM (Mattioli et al., 2006; 
Cortini & Sitia, 2010), the galectin binding protein Mac2-bp (Chen et al., 2013), nicastrin, a 
component of the γ-secretase complex (Morais et al., 2006), the fibroblast growth factor 
receptor FGFR3 (Lievens et al., 2008), and the sulfatase modifying factor I (Fraldi et al., 
2008). 
The interaction of the ERGIC-53 CRD with the N-linked glycans of the cargo molecules 
depends on two factors, namely the Ca2+-concentration and the pH of the local environment. 
While glycan binding is promoted at a slightly basic pH and at a high Ca2+-concentration, as 
it is the case within the ER, substrate release is triggered by a slightly acidic pH and a lower 
Ca2+-concentration, an environment provided by the ERGIC (figure 3a) (Appenzeller-Herzog 
et al., 2004). 
While the CRD of ERGIC-53 has been studied in detail, the oligomerisation domain of the 
protein is less well described at present and there is some confusion over the mechanism of 
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oligomerisation. Two studies have shown that two cysteine residues present in the 
membrane-proximal linker region mediate the oligomerisation of the protein (Appenzeller et 
al., 1999; Lahtinen et al., 1999), but a different study contradicts this claim (Neve et al., 
2005). As the hexamerisation of ERGIC-53 is a prerequisite for its function (Nufer et al., 
2003), further insights into the structure and oligomerisation properties of this domain are 
needed in order to better understand the roles of the oligomeric states of ERGIC-53 in protein 
transport.  
 
Figure 3: (a) Schematic overview of protein transport facilitated by ERGIC-53. The GlcNAc2Man9 glycan of 
correctly folded proteins is recognised by hexameric ERGIC-53 in a Ca2+-dependent manner and the multi-
protein complex is packed into COPII-coated vesicles at ER exit sites. After fission from the ER, the vesicle is 
transported to the ERGIC where the two membranes are fused. The lower Ca2+-concentration within the 
ERGIC triggers the release of the cargo molecule from ERGIC-53, which is subsequently recycled to the ER 
via COPI-coated vesicles. (b) The crystal structure of the ERGIC-53 CRD (magenta) in complex with 
MCFD2 (grey). Calcium-ions are coloured in violet and the carbohydrate recognition site is indicated by an 
arrow (Wigren et al., 2010). 
 
1.4.2 MCFD2 
A connection between ERGIC-53 and MCFD2 was first discovered in 2003, when Zhang et 
al. identified MCFD2 as a second agent causing F5F8D (Zhang et al., 2003). They 
discovered that mutations in the protein led to a phenotype which was indistinguishable from 
the one caused by mutations in ERGIC-53, suggesting it could be acting as a co-transporter 
for these cargo proteins. It was then shown that an MCFD2 knock-down resulted in no 
adverse effect on the localisation of Cathepsin C and Z, indicating that MCFD2 is disposable 
for their transport along the secretory pathway (Nyfeler et al., 2006). It was only in 2013 that 
another protein whose secretion depends on MCFD2 as well as ERGIC-53, namely the Mac2 
binding protein, was discovered by a protein fragment complementation assay (Chen et al., 
2013).   
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In studies designed to investigate whether ERGIC-53 and MCFD2 require each other for 
correct localisation in the cell, siRNA-based knock-down experiments showed that the 
absence of ERGIC-53 led to the secretion of MCFD2, whereas a knock-down of MCFD2 had 
no effect on the localisation of ERGIC-53 (Nyfeler et al., 2006). This result, together with the 
fact that MCFD2 contains no C-terminal KDEL retrieval signal, lead to the conclusion that 
the correct localisation of MCFD2 is dependent on its interaction with ERGIC-53. 
MCFD2 is a soluble, 14 kDa protein found in the ER and ERGIC. The structure of MCFD2 
has been determined by NMR and it revealed that, while the protein is intrinsically 
disordered, it partially folds upon the incorporation of two calcium ions into the two calcium-
binding EF-hand motifs at its C-terminus. The N-terminus, however, remains disordered even 
in the Ca2+-bound state (Guy et al., 2008), and the function of this disordered N-terminal 
region is not currently known. The C-terminal EF-hand domains mediate the interaction with 
the ERGIC-53 CRD, and the crystal structure of the ordered region of MCFD2 in complex 
with the ERGIC-53 CRD has been determined (Nishio et al., 2010; Wigren et al., 2010). 
MCFD2 binds to the ERGIC-53 CRD at a site opposite to the carbohydrate recognition site 
(figure 3b), and the study also showed that most F5F8D-causing mutations lie at the interface 
of the two proteins, suggesting that a disruption of the protein complex is responsible for the 
reduced plasma concentrations of the two coagulation factors.  
 
1.4.3 The ER Vesicle Protein Complex Erv41p/Erv46p 
While a great deal is already known about the role of ERGIC-53 as a glycoprotein transport 
receptor, comparatively little was known about the other main target of this thesis, the 
Erv41p/Erv46p complex, when the study was initiated. In 2001, Otte et al. first described the 
Erv41p/Erv46p protein complex in yeast. By performing a reconstituted COPII vesicle 
budding assay, aiming at the identification of novel proteins of the early secretory pathway, 
combined with mass-spectrometry experiments, both Erv41p and Erv46p were identified, and 
they were named based on their cellular localisation and apparent mass. Further experiments 
determined that the two proteins are conserved across species, that they co-localise to the ER 
and Golgi apparatus and that they are present within the cell as a protein-protein complex. 
Knock-out experiments showed that their expression levels in yeast are interdependent, and 
that yeast cells lacking either protein are viable but susceptible to cold-shock. Further, cell-
free, experiments suggested that the protein complex is involved in membrane fusion (Otte et 
al., 2001). It is now however suspected that this effect is caused by indirect consequences of 
the double knock-out mutants (Shibuya et al., 2015). 
 
Since their initial discovery, the protein complex consisting of Erv41p and Erv46p has been 
investigated more thoroughly. Both proteins are integral membrane proteins, consisting of a 
large, lumenal domain flanked by one transmembrane helix on each side and short 
cytoplasmic tails. While both Erv41p and Erv46p contain a di-hydrophobic sorting motif, IL 
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and FT respectively, for the anterograde transport from the ER to the Golgi apparatus, only 
Erv46p contains a di-acidic KKXX motif signalling for the retrieval of the protein from the 
Golgi apparatus to the ER (Otte & Barlowe, 2002).  
The function of the Erv41p/Erv46p protein complex was initially not well understood, and 
suggestions ranged from an involvement in the sorting of proteins into transport vesicles, to a 
role in the retention and/or retrieval of transport machinery to the early secretory pathway, a 
role in the transport of lipids or, finally, a role in the posttranslational maturation of secretory 
proteins such as protein folding or glycosylation (Otte et al., 2001). It was only in 2014 that 
Noda et al. first showed by domain-switching experiments that the ER-exit of the putative 
mannosyltransferase Ktr4p relied directly on the Erv41p/Erv46p complex, thereby 
confirming a role for the complex in protein sorting (Noda et al., 2014). Since then, another 
study has identified the Erv41p/Erv46p protein complex as a new retrograde receptor for the 
retrieval of non-HDEL bearing ER-resident proteins. Erv41p/Erv46p double knock-out 
strains led to the secretion or mislocalisation of the Mannosyl-oligosaccharide glucosidase 
Gls1 and the Peptidyl-prolyl cis-trans isomerase Fpr2, two ER-resident proteins (Shibuya et 
al., 2015). Moreover, this study showed that the interactions between the Erv41p/Erv46p 
complex and Gls1 are regulated by pH. The interaction is strong in the slightly acidic 
environment provided by the Golgi apparatus and substantially weaker at the slightly basic 
pH provided by the ER. The conclusion drawn from the combination of these experiments is 
therefore that the Erv41p/Erv46p complex binds escaped ER-resident proteins within the 
Golgi apparatus and retrieves them to the ER, where they are released.  
In humans, homologous proteins of Erv41p and Erv46p can be found as members of a three-
component protein complex consisting of ERGIC1, ERGIC2 and ERGIC3. While Erv41p 
and Erv46p share 30% and 41% sequence identity with ERGIC2 and ERGIC3, respectively, 
ERGIC-1 lacks a homologous protein in yeast. ERGIC1 shares the domain topology of the 
other members of the complex, and interacts directly with ERGIC3 (Breuza et al., 2004) but 
is mainly localised to the ERGIC. While the human proteins are much less well characterised, 
studies have suggested an involvement of all three proteins in different types of cancer. The 
ERGIC1 gene has been shown to be highly expressed in prostate cancer tissue and suggested 
to be a potential drug target (Vainio et al., 2012), the ERGIC2 gene has been found to 
upregulate interferon-β in a prostate cancer cell line (Kwok et al., 2006), and the ERGIC3 
gene has been suggested as a potential biomarker for lung cancer (Lin et al., 2015). 
 
1.4.4 Ktr4p, a Cargo of the Erv41p/Erv46p Complex 
The first protein to be identified as cargo of the Erv41p/Erv46p complex was the putative 
glycosyltransferase Ktr4p, a member of the Kre2/Mnt1 family of in S. cerevisiae. Our 
knowledge of this family of proteins dates back to 1991, when Hill et al. first cloned and 
sequenced the KRE2 gene from the yeast S. cerevisiae and found that it shares significant 
sequence identity with two previously identified proteins, termed KTR1 and Yur1p, and the 
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common domain topology consistent with type II membrane proteins, in concert with the 
location of the most conserved regions, suggested a related function. The three proteins were 
therefore classified as a family (Hill et al., 1992), and since their first classification, six 
additional proteins have been identified as members of the Kre2/Mnt1-family. 
The enzymatic activities of six members of the family have been studied, and, while five have 
been shown to possess glycosyltransferase activity, one enzyme, namely Ktr6p, has been 
shown to instead have mannosylphosphate transferase activity (Wang et al., 1997; Jigami & 
Odani, 1999). Kre2/Mnt1 is the best characterised member of the family. It catalyses the 
addition of the second and third α-1,2-linked mannose residues in linear O-linked 
oligosaccharides, and has also been shown to be involved in the synthesis of the outer chains 
of N-linked oligosaccharides (Hill et al., 1992; Lussier et al., 1996, 1997). A crystal structure 
of the lumenal, catalytically active, domain of Kre2/Mnt1 has also been determined, and the 
structure shows the lumenal domain to be comprised of a single, Rossmann-fold-type  
domain with an adjacent second domain of α/β-structure, and thus to belong to the GT-A fold 
family of glycosyltransferases, rather than the GT-B fold family which has two, less tightly-
packed, Rossmann-like domains with the active site in a cleft between them (Lobsanov et al., 
2004). 
When initiating our studies, the knowledge of Ktr4p was very limited in comparison to Kre2. 
Sequence alignments showed that it exhibits a 32% identity to Kre2p/Mnt1p , with the 
residues constituting the active site, including those responsible for the binding of the GDP-
nucleotide and the Mn2+-ion, being largely conserved.  This comparison implied that the 
function of Ktr4p is similar to that of Kre2p/Mnt1p, but no in vitro enzyme activity assays 
have been performed prior to the experiments described in this thesis. Gene knock-out studies 
have been performed in the filamentous fungi Beauvaria bassiana and these led to growth 
defects, a decrease in cell wall components, reduced tolerance to stress and lower virulence 
(Wang et al., 2014), reinforcing the potential importance of the Ktr4p protein. 
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2 AIM OF THE THESIS 
 
The general aim of this thesis was the characterisation of proteins or protein-protein 
complexes involved in glycoprotein transport or processing in the early secretory pathway. 
More specifically, the aims were 
• to elucidate the three-dimensional structure of Erv41p and study its interaction with 
Erv46p, 
• to enzymatically and crystallographically characterise Ktr4p, and 
• to study the structure of the full lumenal part of ERGIC-53 and to investigate its 
oligomerisation properties. 
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3 RESULTS AND DISCUSSION 
3.1 EXPRESSION, PURIFICATION AND X-RAY STRUCTURE 
DETERMINATION OF ERV41P (PAPERS I & II) 
The membrane protein complex comprised of Erv41p and Erv46p in yeast initially attracted 
our interest when it was first hypothesised to be involved in the transport of cargo proteins 
between the ER and the Golgi apparatus. While only a handful of studies on the yeast protein 
complex were published at the time, even fewer articles described the role of the human 
orthologues ERGIC1, ERGIC2 and ERGIC3. Most strikingly, our bioinformatic analyses 
showed little sequence similarity between these proteins and any protein structure deposited 
in the PDB, which severely hindered prediction of their functions. In order to better 
understand their potential functions, we therefore initiated a project to investigate the 
structures of these proteins, as well as the interactions between them. 
 
3.1.1 Expression and Purification of Erv41p and Erv46p 
As extensive trials to produce soluble Erv41p and Erv46p in E. coli in our laboratory had 
previously failed, we decided to instead utilise the baculovirus expression vector system for 
the recombinant expression of these proteins. In this system, ovarian cells from either of two 
organisms, Spodoptera frugiperda or Trichoplusia ni, are transfected with a viral bacmid, 
engineered to contain the gene of interest. This gene is cloned at the location of the 
dispensable polH gene, which, in the wildtype virus, encodes for the protein polyhedrin, a 
major structural component of baculovirus occlusion bodies. In this eukaryotic expression 
host it is possible to direct expression of recombinant proteins through the secretory pathway 
to the extracellular medium, thus employing the folding and quality control mechanisms in 
the host cell ER, by attaching a signal sequence to the N-terminus. We therefore chose to 
include the signal sequence of honey bee mellitin - the active component in bee venom, and a 
highly expressed and efficiently secreted protein – at the N-terminus of each construct, and 
this was followed by a His6-purification tag. For this work, we decided to omit the N- and C-
terminal transmembrane helices of both Erv41p and Erv46p, as well as their cytoplasmic 
tails, and aimed to produce only the lumenal domain of each protein. Several constructs were 
Figure 4: Schematic representation of the domain topology of Erv41p and Erv46p. Both wildtype proteins are 
comprised of a single lumenal domain flanked by a transmembrane helix (TM) on each side and short, 
cytoplasmatically exposed, N- and C-termini. While Erv41p only contains a C-terminal anterograde transport 
motif, Erv46p contains both antero- and retrograde transport motifs at its C-terminus. The constructs studied in 
this work, comprised only of the lumenal domain of each protein, also are depicted. 
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tested for expression and, ultimately, the longest constructs, spanning residues 49 - 297 and 
49 - 372, for Erv41p and Erv46p, respectively, were used in this study (figure 4).  
Following the transfection of S. frugiperda Sf9 cells with the bacmid, and confirmation of 
production and secretion of the recombinant protein, each protein was produced in larger 
scale by infecting T. ni High Five cells with the respective virus. Both proteins could then be 
purified from the expression medium by standard techniques. 
Using these methods, we were able to successfully express and purify Erv41p_LD and 
Erv46p_LD of suitable qualities and in suitable quantities to proceed with crystallographic 
studies. 
 
3.1.2 Structure Determination of Erv41p 
Crystallisation trials with Erv41p were performed using commercially-available screens, and 
resulted in one condition producing diffracting crystals. Optimisation of this condition was 
successful, and X-ray diffraction data to 2.0 Å resolution was recorded. Since no phase 
information from a homologous or structurally similar protein was available, the single 
anomalous dispersion method was employed to experimentally obtain the information for 
initial phasing of the structure. To achieve this, crystals of the native protein were soaked 
with a range of metals or heavy metal containing compounds, and many soaked crystals were 
screened for diffraction on synchrotron beamlines. Ultimately, only crystals soaked with 
YbCl3 diffracted to a high enough resolution (2.7 Å) and provided sufficient anomalous 
signal to enable the placement of the strongly diffracting heavy atoms and make initial model 
building possible. At this stage, elongated sections of electron density, clearly corresponding 
to β-strands, could be identified and a poly-alanine model was built to fit the density. After 
several rounds of phase combination, model building and refinement, this model was of high 
enough quality to be used as a molecular replacement search model for the higher-resolution 
dataset recorded from the native crystals, and model building was completed with this 
dataset. The final model at 2.0 Å resolution was refined to R/Rfree values of 16.5% and 
20.6%, respectively, and comprises the full lumenal domain of Erv41p, with the exception of 
three flexible loops. 
 
 
 
 
 
 
  19 
Table 2: Summary of data collection, phasing and refinement statistics for Erv41p_LD. Statistics for the highest-
resolution shell are shown in parentheses. 
 
3.1.3 The Structure of Erv41p 
The lumenal domain of Erv41p consists of a tightly packed and twisted β-sandwich, whose 
concave and convex faces are comprised of an eight-stranded β-sheet (sheet A) and a six-
stranded β-sheet (sheet B), respectively. On one side of the β-sandwich the β-strands are 
connected by loops, some of which contain short helices, while on the other side, short N- 
and C-terminal β-strands protrude from the core. Since the native protein contains 
transmembrane helices at the N- and C-termini, this would be the membrane-proximal side 
(figure 5a,b). 
 Erv41p_LD/YbCl3 Erv41p_LD native 
Data collection and phasing   
Wavelength [Å] 1.3852 0.9334 
Resolution range [Å] 48.24-2.7 (2.85-2.7) 48.14-1.99 (2.10-1.99) 
Space group P21 P21 
Unit cell parameters   
  a, b, c [Å] 
  α, β, γ [º] 
48.77, 76.65, 65.47 
90, 98.49, 90 
49.78, 76.93, 65.11 
90, 104.7, 90 
Total reflections 77603 127463 
Unique reflections 12968 31843 
Multiplicity 6 (6.2) 3.9 (3.2) 
Completeness [%] 98.4 (97.2) 99.1 (94.2) 
Mean I/σI 18.6 (7.3) 19.41 (4.41) 
Anomalous completeness [%] 94.9 (93.5)  
Anomalous multiplicity 3.1 (3.1)  
Wilson B-factor [Å2] 34.8 23.1 
Rmerge 0.064 (0.19) 0.05 (0.27) 
Phasing Figure of Merit 0.432  
Refinement   
R/Rfree [%]  16.5/20.6 (18.8/23.0) 
Number of atoms  3868 
  macromolecules  3628 
  water  240 
Protein residues  432 
Average B-factor, including TLS contribution [Å2]  36.40 
  macromolecules  33.4 
  solvent  39.8 
R.M.S. deviations from ideal   
  RMSD bond lengths[Å]  0.009 
  RMSD bond angles [º]  1.21 
Ramachandran plot   
  Ramachandran favored [%]  95 
  Ramachandran outliers [%]  0 
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Figure 5: The structure of Erv41p_LD. (a) The structure of Erv41p_LD is represented as a cartoon and coloured 
according to secondary structure elements, with α-helices in gold, β-sheets in blue and loops in grey. The 
secondary structure elements are labelled, and missing sections of loops are indicated by dashed lines. A 
schematic representation of the ER-membrane shows the position of the lumenal domain in the context of the 
full protein. (b) A representation of the structure rotated by 90º around a vertical axis. (c) The electrostatic 
potential of the Erv41p_LD surface. The orientation of the protein is equivalent to (a). Negative potential is 
denoted in red and positive potential is denoted in blue. The maps were calculated using the APBS plug-in to 
PyMOL and are contoured at the 4-kT level. (d) A view of the structure rotated by 180º around a vertical axis. 
 
Calculation of the electrostatic surface potential of the Erv41p lumenal domain reveals a 
large, negatively charged area covering almost the entire sheet B, while on the opposite sheet 
A, only singular charged residues stand out from the largely neutral surface. The size of this 
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negatively charged area led us to the hypothesis that it is likely to be physiologically relevant, 
possibly as a site of interaction with other proteins or smaller ligands (figure 5c,d). 
Searching the PDB for structurally similar proteins identified, among others, acid-sensing ion 
channels and other structures of proteins with carbohydrate binding modules. However, due 
to the low similarity of even the closest structural relatives with root mean square deviations 
(RMSD) of 4.4 Å and 3.7 Å, respectively, no meaningful conclusion about the function of 
Erv41p can be drawn from these comparisons. 
 
3.1.4 Expression, Purification and Crystallisation of Erv46p 
As with Erv41p, exhaustive trials to express Erv46p in E. coli yielded only insoluble protein 
and the gene was therefore cloned for expression in insect cells. A construct lacking the 
transmembrane helices, but covering the full lumenal domain, with an N-terminal honeybee 
mellitin signal sequence was engineered and insect cells were transfected with the resulting 
bacmid. The protein could be purified from the culture medium via its N-terminal His6-tag, 
but upon removal of this purification tag a large fraction of the protein formed soluble 
aggregates, which could not be recovered. Nevertheless, some monomeric protein remained 
in solution, and several commercial crystallisation screens were set up to identify suitable 
conditions for the crystallisation of Erv46p_LD. Microcrystals could indeed be produced, 
however these crystals did not diffract at synchrotron beamlines. After optimisation of the 
condition to produce larger and diffracting crystals failed, further screening for different 
conditions was performed. Three-dimensional crystals were obtained at this point, however 
they were later revealed to be of a contaminant protein (described in further detail in paper 
IV). 
 
3.1.5 Interaction Studies of Erv41p and Erv46p 
In order to gain further insight into the strength and mechanism of interaction between 
Erv41p and Erv46p, we performed surface plasmon resonance (SPR) experiments with the 
two proteins. Due to the tendency of Erv46p_LD to form soluble aggregates however, our 
studies were ultimately limited to showing the direct and concentration-dependent interaction 
of the two proteins in vitro.  
The experiments were performed on a Biacore 3000 instrument (GE Healthcare, Uppsala, 
Sweden) at 25 ºC. Erv41p_LD was immobilised on a CM5 chip by amine-coupling according 
to standard procedures (GE Healthcare) in acetate buffer, pH 4, leading to a response of  
700 RU, and Erv46p_LD was used as the analyte and injected onto the chip in varying 
concentrations and in a random order at a flow-rate of 100 µl/min. An unmodified flow-cell 
was used as a reference surface. After each analyte injection, the surface was regenerated 
with short pulses of 5 mM NaOH. Evaluation of the sensorgrams was performed using 
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BIAevaluation 4.1 (GE Healthcare), and the reference signal was subtracted from the raw 
data (figure 6). 
Since Erv41p and Erv46p have been observed as a part of a larger complex of 200 - 400 kDa 
(Welsh et al., 2006), the possibility that as-yet unidentified adapter proteins maintain an 
indirect interaction between Erv41p and Erv46p had to be considered. In addition, the 
transmembrane helices might be involved in the assembly of the complex. While the SPR 
experiments confirm that the interaction between the lumenal domains of the two proteins is 
direct, the low response upon binding points towards a weak and possibly transient 
interaction between the two proteins. 
 
Figure 6: SPR sensorgram of Erv41p_LD interacting with Erv46p_LD. Erv41p_LD was immobilised on a CM5 
chip and Erv46p_LD was used as the analyte. Four injections of analyte concentrations ranging from 1.1 µM to 
8.8 µM were performed in random order and reference data from an unmodified flow-cell was subtracted. The 
results indicate a direct binding of Erv46p_LD to Erv41p_LD. 
 
3.1.6 Expression and Crystallisation of ERGIC1 
ERGIC1, the third member of the human protein complex, which lacks a yeast homologue, 
was cloned, expressed and purified in the same manner as Erv41p, and attempts to crystallise 
the protein were undertaken. Unfortunately, as for Erv46p, only very small crystals could be 
obtained, which diffracted poorly, and optimisation of these crystals was not successful 
despite extensive efforts. 
 
  23 
3.1.7 Co-expression of ERGIC1, ERGIC2 and ERGIC3 
In addition to the expression of Erv41p and Erv46p, we also attempted to co-express the 
tripartite complex of the homologous human proteins in insect cells. This was facilitated by 
the use of the co-expression system developed for the BEVS by Fitzgerald et al., (Fitzgerald 
et al., 2006), which provides two plasmids, each containing two multiple cloning sites 
(MCS). This allows one to make use not only of the polyhedrin promotor, but also the 
promotor of the gene encoding for p10 - another viral protein dispensable for infectious virus 
formation which is replaced by the second gene of interest. The two plasmids can be 
recombined using the Cre-Lox technology. After engineering a plasmid containing all three 
human proteins, transfection of insect cells and protein production is carried out as usual. 
Using these techniques, we successfully co-expressed the lumenal domains of ERGIC1, 
ERGIC2 and ERGIC3, which could then be co-purified in small amounts. Unfortunately, the 
very low yields resulting from the co-expression of the proteins prevented further studies to 
investigate the complex. 
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3.2 THE CRYSTAL STRUCTURE OF KTR4P FROM S. CEREVISIAE (PAPER III) 
In yeast, the family of Kre2/Mnt1 glycosyltransferases consists of nine members, which have 
been shown to play roles in N- and O-linked glycosylation of newly synthesised proteins. 
Several of the members of this family have been characterised and shown to catalyse similar 
and partially redundant mannosyltransferase reactions (Lussier et al., 1999), and one member 
has been shown to be a mannosylphosphate transferase (Wang et al., 1997; Jigami & Odani, 
1999). These enzymes are mostly located to the Golgi apparatus, and in 2014, the location of 
one member of the family, Ktr4p, was shown to directly depend on the presence of the ER 
vesicle proteins Erv41p and Erv46p (Noda et al., 2014). This study brought Ktr4p to our 
attention and we decided to produce recombinant Ktr4p with the aim of both studying the 
protein itself, and of potentially performing interaction studies together with Erv41p and 
Erv46p. 
 
 
Figure 7: Schematic representation of the domain topology of Ktr4p. The wildtype protein is comprised of a 
short, cytoplasmatically exposed tail at the N-terminus, followed by a transmembrane helix, a lumenal stem 
domain and a large catalytic domain. The construct studied in this work, comprised only of the lumenal part of 
the protein is also depicted. TM: transmembrane helix. 
 
3.2.1 Expression and Purification of Ktr4p 
For the production of the putative glycosyltransferase Ktr4p, attempts to express the protein 
in E. coli succeeded. Twelve constructs of the lumenal domain of the protein, with the longest 
one ranging from residues Asn-33 to Tyr-464 (figure 7), were each cloned into the pNIC28-
Bsa4 plasmid, which contains a His6-purification tag N-terminal of the MCS. The actual 
cloning was carried out by the Protein Science Facility at Karolinska Institutet, although all 
subsequent work was performed in our laboratory. Given the eukaryotic origin of the protein 
and its subcellular location in the Golgi apparatus, combined with our previous experience of 
expressing these proteins in a bacterial host, the E. coli Rosetta-gami 2 strain was chosen as 
the expression host. The Rosetta-gami 2 strain combines the features of the Rosetta strain, 
allowing for enhanced disulfide bond formation, and the Origami strain, enhancing the 
expression of eukaryotic proteins containing rare codons scarcely used in E. coli. We were 
pleasantly surprised to learn that all correctly cloned constructs led to soluble protein using 
this E. coli strain. After the successful small-scale expression trials, the production of all 
tested constructs could be scaled up and approximately 20 mg of pure protein could be 
obtained from a 1 litre E. coli culture by following standard expression and purification 
protocols. While the purification of some constructs resulted in the presence of a degradation 
product, the longest construct, ranging from residues Asn-33 to Tyr-464 could be isolated to 
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purity without signs of degradation. We therefore chose to focus only on this construct in 
subsequent studies. The integrity of the protein preparation was investigated with circular 
dichroism (CD), which confirmed that the protein was folded and showed that its secondary 
structure content was mostly α-helical, and dynamic light scattering (DLS), which indicated a 
monodisperse sample.  
 
3.2.2 Crystallisation and Structure Determination 
Crystallisation trials using the sitting drop method were set up in 300 nl drops with 
commercially available screens, and crystals were harvested directly from one condition of 
the screening plates. These crystals diffracted to 2.2 Å resolution, and data were collected at 
beamline ID23-1 of the ESRF. The structure was solved by molecular replacement, using the 
already available structure of Kre2/Mnt1 (PDB id 1S4N, (Lobsanov et al., 2004)) as a search 
model, and after model building refined to R/Rfree values of 0.16/0.20, respectively. 
 Ktr4p_LD apo structure Ktr4p_LD-GDP complex  
Data collection   
Beamline ESRF ID23-1 ESRF ID23-2 
Wavelength [Å] 0.8726 0.97241 
Space group P212121 P212121 
Unit cell parameters   
   a, b, c [Å] 60.19, 102.37, 156.91 61.215, 102.62, 162.65 
   α, β, γ [º] 90, 90, 90 90, 90, 90 
Resolution [Å] 50-2.2 (2.28-2.20) 50-1.9 (1.94-1.90) 
Rmerge  0.127 (0.651) 0.104 (0.867) 
Mean I/σI 13.8 (3.0) 15.5 (2.3) 
Mean CC1/2 0.997 (0.856) 0.999 (0.833) 
Completeness [%] 99.7 (97.0) 99.1 (98.9) 
Multiplicity 7.8 (8.0) 9.8 (9.2) 
Number of reflections 387144 (34874) 790203 (41691) 
Number of unique reflections 49596 (4381) 80667 (4508) 
Wilson B-factor [Å2] 10.5 17.5 
Refinement   
Resolution [Å] 50 - 2.2 50 - 1.9 
R/Rfree 0.163/0.202 0.156/0.191 
Number of non-hydrogen atoms (protein) 7081 7278 
Mean B value [Å2] 24.96 26.51 
Number of waters 498 577 
R. M. S. deviations from ideal   
  RMSD bond lengths [Å] 0.018 0.20 
  RMSD bond angles [º] 1.678 1.832 
Ramachandran plot   
  Residues in favoured regions [%] 97.8 98.2 
  Residues in allowed regions [%] 2.2 1.8 
  Residues in disallowed regions [%] 0 0 
Table 3: Summary of data collection and refinement statistics of Ktr4p_LD and Ktr4p_LD bound to GDP and 
Mn2+. Statistics for the highest-resolution shell are shown in parentheses. 
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By incubating the protein with both GDP and MnCl2 for 1h, followed by the same 
crystallisation procedure as for the apo-protein, crystals of Ktr4p_LD bound to both Mn2+ and 
GDP could be obtained, and diffraction data to 1.9 Å were recorded at beamline ID23-2 of 
the ESRF. The previously obtained apo-structure of Ktr4p_LD was used as a search model 
for molecular replacement. During refinement of the protein chain, clear density 
corresponding to a GDP-molecule became apparent in the active site of both chains in the 
asymmetric unit. The structure was ultimately refined to R/Rfree values of 0.16/0.19, 
respectively (data collection and refinement statistics are shown in table 3).  
 
3.2.3 The Crystal Structure of Ktr4p 
The structure of Ktr4p is comprised of a central seven-stranded β-sheet, which is surrounded 
by several α-helices and flanked by two β-strands (figure 8a). With this structure it belongs to 
the glycosyltransferase subfamily GT-A, and it aligns to Kre2/Mnt1, the closest homologue 
with a determined structure, with an RMSD of 1.2 Å over 235 residues of the catalytic 
domain. This striking similarity, despite the relatively low sequence identity of 32%, is also 
apparent in the active site of the enzymes, which led to the hypothesis that Ktr4p binds GDP, 
coordinated by a Mn2+ ion, two ligands that are both present in the structure of Kre2/Mnt1. 
This hypothesis was tested by incubating the protein with GDP and MnCl2 prior to 
crystallisation, and both ligands were indeed clearly identifiable in the active site of the 
resulting structure (figure 8b). In contrast, the soaking experiments performed with a 
relatively high concentration of methyl-α-mannoside led to only very weak density visible at 
the proposed binding site for the acceptor, which would suggest a very weak binding of the 
monosaccharide at this position. Similarly weak density was observed when analogous 
experiments were performed with Kre2/Mnt1 (Lobsanov et al., 2004). This weak binding 
could either be an indication of a non-native acceptor substrate, which possibly decreases its 
binding affinity to the active site substantially, a very fast dissociation rate of the acceptor 
substrate, or a combination of the two. 
Upon comparison of the apo-structure with the GDP-complex, the only striking differences 
are observed in the active site, with the main rearrangement being the displacement of  
Arg-142 to allow the binding of GDP in the active site. The preformed nature of the active 
site is relatively unusual in glycosyltransferases; it is more common that conformational 
rearrangements of loops are observed upon ligand binding. The loops covering the active site 
of the enzyme are thought to sequester the active site from the solvent and potentially assist in 
product release (Unligil & Rini, 2000). 
 
3.2.4 Activity assay 
Since the activity of Ktr4p had not been previously studied and had been only speculated to 
be that of a glycosyltransferase, experiments to confirm its function were performed using a 
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coupled malachite-green assay. In this experiment, the glycosyltransferase reaction of Ktr4p 
(figure 8c) is assayed via GDP, the proposed leaving product of Ktr4p. GDP is further 
hydrolysed by the nucleotidase ENTPD3/CD39L3, giving rise to free inorganic phosphate, 
which can subsequently be detected and quantified using the malachite green reagent. This 
activity assay was performed using GDP-mannose as the sugar donor and three potential 
acceptor substrates were tested, namely mannose, α-1,2-mannobiose and methyl-α- 
mannoside. The choice of these donor- and acceptor-substrates was based on suggestions 
from sequence identity to Kre2/Mnt1 and commercial availability. Our results show that 
Ktr4p indeed is an active mannosyltransferase and the most efficient mannosyltransfer was 
observed for methyl-α-mannoside, while the observed reaction rates for mannose and α-1,2-
mannoside were very low (figure 8d). 
 
Figure 8: The crystal structure and enzymatic activity of Ktr4p_LD. (a) The structure of Ktr4p_LD in complex 
with GDP and Mn2+. α-helices are coloured in green, 310-helices in black and β-strands in orange, and all 
secondary structure elements are numbered. The GDP is shown in ball-and-stick representation, as are the 
cysteines forming disulfide-bonds. (b) Ball-and-stick representation of GDP (white) and Mn2+ (purple) located in 
the active site and residues involved in their binding (green). (c) The glycosyltransfer reaction catalysed by 
Ktr4p. (d) Activity of Ktr4p_LD. The enzyme is active using methyl-α-mannoside (■) as acceptor substrate, and 
the signal observed using α-1,2-mannobiose (♦) and D-mannose (▲), respectively, is comparable to the 
background reading in the absence of acceptor substrate (+). The blank reading, measured in the absence of 
enzyme, has been deducted from all experimental readings. 
 28 
These three acceptor substrates might only represent a fraction of the native substrate of 
Ktr4p. While our results clearly prove the mannosyltransferase activity of the enzyme, further 
experiments using the biological acceptor substrate, possibly attached to a target protein or 
lipid, might lead to further insight into the selectivity and activity of the protein. The 
identification of this substrate was however a task beyond the scope of this study for several 
reasons. Generally, the substrates of glycosyltransferases are tremendously hard to identify, 
and intricate knowledge of their roles in a specific pathway is required. This in turn would 
demand knowledge of the individual glycosylation remodelling steps of the substrate, leading 
to a Catch-22 situation. While an in silico approach to identify classes of substrates based on 
the protein's coding region is available for bacteria (Sánchez-Rodríguez et al., 2014), in most 
cases the only readily available option is a microarray-based glycan screen. For this, a 
collection of glycans is immobilised on a microarray and binding of a protein in question to 
specific substrates can be tracked by antibodies.  
We have undertaken this approach and screened for binding of Ktr4p_LD in the presence of 
Mn2+ at a pH of 6.5, the physiologial pH within the Golgi apparatus (Paroutis et al., 2004), to 
a selection of over 600 natural and synthetic mammalian glycans in collaboration with the 
Consortium for Functional Genomics. The results of this assay were however negative, as no 
binding of Ktr4p_LD to any of the screened glycans was observed. It therefore has to be 
considered that Ktr4p might indeed not interact with complex glycans. Other possible 
explanations for the lack of an observed signal are however manifold: the interactions could 
be weak and transient and not give rise to a detectable signal. This might be caused by non-
native experimental conditions, such as a too high or too low pH-value, improper ionic 
strength of the solvent or the lack of a co-factor. While the early steps of N-linked 
glycosylation in the ER of yeasts resemble those of humans, later stages of glycan 
remodelling, especially of O-linked glycans, differ greatly between the two organisms (Van 
den Steen et al., 1998). It is therefore possible that the chosen array of mammalian glycans, 
which does not cover the complete human glycome, does not incorporate the actual substrate 
of Ktr4p from yeast.  
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3.3 FERRITIN FROM THE EXPRESSION HOST T. NI IS A COMMON 
CRYSTALLISATION CONTAMINANT (PAPER IV) 
In our laboratory, the application of the baculovirus expression vector system for the 
production of eukaryotic proteins localised to the early secretory pathway has proven to be 
successful in many cases, and a substantial number of proteins that had previously proven 
unamenable for expression in E. coli strains could be produced using this technology. For the 
expression of secretory proteins, an N-terminal honeybee mellitin secretion signal was added 
to the protein sequence, followed by a His6-purification tag and a TEV cleavage site. For 
large-scale production of these proteins, the BTI-TN5B1-4 (High Five) insect cell strain, a 
cultured cell line originated from the ovarian cells of the cabbage looper Trichoplusia ni, was 
used. This cell line had been previously reported to produce higher expression yields, 
especially for secreted proteins  (Krammer et al., 2010; Wilde et al., 2014), an observation 
confirmed in our studies, as the High Five strain routinely increased expression yields up to 
10-fold compared to the Sf9 cell line. 
The recombinant proteins were purified by standard techniques, small-scale crystallisation 
screens were set up, and in the cases of Erv46p and the ERGIC-53 4H/MCFD2-∆N complex, 
small crystals were obtained (figure 9b). In the case of the Erv46p protein preparation, 
crystals grown in five different conditions diffracted to ~2.2 Å resolution without 
optimisation. For the ERGIC-53 4H/MCFD2-∆N complex, the crystals could reproducibly be 
obtained and increased in size after drops of larger volumes were set up, finally leading to 
diffraction up to ~4 Å resolution. 
As molecular replacement search models for both proteins were available, this method was 
employed in order to solve the structures. It however never led to any convincing solutions, 
and rather to the suspicion that a protein contaminant had crystallised instead of the target 
proteins. In the case of Erv46p, this contaminant was readily identified by querying the PDB  
 
Figure 9: (a) SDS-PAGE analysis of purified Erv46p_LD and hexameric ERGIC-53 4H in complex with 
MCFD2-∆N. Asterisks indicate the molecular mass of the ferritin heavy and light subunit. (b) Crystals of ferritin 
grown in six different conditions. The crystals labelled a-e were obtained from contaminated Erv46p 
preparations, and the one labelled f from ERGIC-53 preparations. (c) A section of the unbiased Fo-Fc omit map 
after molecular replacement, confirming that attempts to crystallise Erv46p_LD instead resulted in T. ni ferritin 
crystals. A section of the T. ni ferritin structure is shown in green and the Fo-Fc omit map, which was produced 
by running refinement after deleting this section of the structure from the model, is depicted as grey mesh. 
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for similar unit cell dimensions, which led to the previously-published structure of ferritin 
from T. ni. The structure could subsequently be solved using this molecule as a search model, 
and it was refined to R/Rfree-values of 0.24/0.26, respectively, and the quality of the electron 
density confirmed beyond doubt that the crystals indeed were of T. ni ferritin (figure 9c). 
In the case of the complex of ERGIC-53 4H and MCFD2-∆N however, no protein with 
similar unit cell parameters could be found in the PDB and the structure solution process was 
therefore more cumbersome. Ultimately though, with our previous experience in mind, an 
attempt to solve the structure using T. ni ferritin as a search model for molecular replacement 
was undertaken and the structure could readily be solved and refined to R/Rfree-values of 
0.30/0.34, respectively. In both cases, no extensive structure refinement was undertaken as a 
higher-resolution structure of T. ni ferritin is already available (Hamburger et al., 2005).  
The iron-storage protein ferritin of insects is a spherical 24-mer consisting of twelve heavy 
(26 kDa) and twelve light (24 kDa) chains. It is mostly found in the rER, and ferritin crystals 
can even be observed in secretory vesicles by electron microscopy (Locke & Leung, 1984; 
Nichol et al., 2002). In D. melanogaster fly extract, ferritin was found to be a major 
constituent, representing 0.8% of the total protein content (Li, 2010). Clearly, ferritin is 
highly abundant in baculovirus infected cells as well, and it co-elutes from Ni-NTA 
Sepharose beads with the His6-tagged target protein (figure 9a). The fact that it is still present 
in the sample after removal of the His6-purification tag from the target protein by incubation 
with TEV protease, followed by a reversed IMAC step, is surprising. However it might be 
attributed to its large quantities; weak binding of large amounts of ferritin to a Ni-NTA 
matrix might lead to removal of a large portion in the flow-through, but some ferritin could 
still be retained during the purification. Similarly, during the reversed Ni-NTA purification 
step, ferritin might be found in the flow through. Erv46p_LD was further purified by SEC 
and the fractions eluting at the volume corresponding to ~400 kDa were pooled and 
concentrated. While the exact molecular mass of T. ni ferritin remains unknown, it can be 
estimated to ~600 kDa. In the case of the ERGIC-53 4H/MCFD2-∆N complex, the protein 
peak eluting at a volume corresponding to ~100 kDa was collected and re-injected onto the 
SEC column, yielding a fraction of hexameric protein eluting at a volume corresponding to 
~300 kDa. This fraction was then incubated with MCFD2-∆N in the presence of CaCl2 and 
once again analysed by SEC, which clearly showed the presence of a stable complex eluting 
at a volume corresponding to ~360 kDa.  
As the shapes of both Erv46p and the ERGIC-53 4H/MCFD2-∆N complex might be non-
globular, their elution volumes might differ more profoundly from their theoretical molecular 
masses. This could be an explanation for the presence of ferritin in Erv46p preparations, it 
does however not hold in the case of the ERGIC-53 4H/MCFD2-∆N complex, as the latter 
protein sample was originally obtained from the peak eluting at 100 kDa. 
In addition to its persistent presence during protein preparation, T. ni ferritin seems very 
prone to crystallisation in a number of different conditions and at very low concentrations, 
presumably aided by its high internal symmetry. 
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Altogether, we conclude that T. ni ferritin poses a problem when working with High Five 
cells as an expression host, and that protein preparations originating from High Five cells 
should be meticulously inspected for the presence of ferritin at an early stage of 
experimentation.  
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3.4 INVESTIGATING THE OLIGOMERISATION PROPERTIES OF ERGIC-53 
(PAPER V) 
While the carbohydrate recognition function of ERGIC-53 has been well studied (Velloso et 
al., 2002, 2003; Wigren et al., 2010; Zheng et al., 2013), the mode of oligomerisation 
provided by the membrane proximal oligomerisation domain of the protein remains more 
obscure. It has been established that ERGIC-53 is only functional as a hexamer (Nufer et al., 
2003), but we do not yet understand why this is the case, or how the hexamer is built up. 
Experiments aimed at elucidating the structure of the hexameric form, and the mechanisms of 
its interactions with the co-receptor MCFD2 and with cargo, are therefore of key importance 
to increase our understanding of how ERGIC-53 functions as a cargo transport receptor in the 
early secretory pathway. However, despite the efforts of several research groups, it has not 
previously been possible to produce oligomerisation-competent ERGIC-53 protein in a 
recombinant host. We therefore set out to address this problem. 
 
3.4.1 Expression and Purification of ERGIC-53 
While the expression of the CRD of ERGIC-53 in E. coli was feasible, longer constructs 
including the full oligomerisation domain or only parts of it produced either insoluble protein 
or insufficient yields, and the expression of the isolated oligomerisation domain led to similar 
results. Only a construct comprising the CRD and three of the four helices belonging to the 
oligomerisation domain (ERGIC-53 3H) could be produced as soluble protein, and this was 
in minute amounts. 
Two constructs of ERGIC-53, one including the full lumenal part (ERGIC-53 4H+L) and one 
truncation variant lacking the membrane-proximal linker (ERGIC-53 4H), were therefore 
prepared for expression trials in insect cells. Crucially, the ERGIC-53 4H+L construct 
includes the membrane-proximal linker, which contains two cysteine residues (Cys-466 and 
Cys-575) that are the subject of an ongoing debate. Several studies have suggested that these 
cysteines form intermolecular disulfide-bonds and trigger the trimerisation of ERGIC-53 
dimers (Appenzeller et al., 1999; Carrière et al., 1999; Lahtinen et al., 1999), while others 
have suggested that they do not play a crucial role in the assembly of hexameric ERGIC-53 
(Neve et al., 2005). Comparisons of these two constructs would allow for the further study of 
the role of the two cysteine-residues in vitro, and we have therefore focused our work on 
these two (figure 10). 
Each construct was cloned into a plasmid containing a honeybee mellitin secretion signal 
followed by a His6-purification tag N-terminal of the MCS. The bacmid preparation, insect 
cell transfection and large scale production of the constructs were performed using the same 
protocols as for the production of the ER vesicle proteins, and soluble protein could be 
obtained for all tested constructs.  
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Figure 10: Schematic representation of the domain topologies of ERGIC-53 and MCFD2. ERGIC-53 is a  
53 kDa protein comprised of a lumenal carbohydrate recognition domain (CRD) at its N-terminus and an 
oligomerisation domain predicted to consist of four α-helices (I - IV). This domain is followed by a short region 
linking the lumenal part of the protein to the ER membrane, which includes two cysteine residues (Cys-466 and 
Cys-475). On the cytoplasmic side, ERGIC-53 exposes a short C-terminal tail including the sorting motifs for 
both antero- and retrograde transport. The different C-terminal truncation variants of ERGIC-53 used in this 
study are represented below. 
Wildtype MCFD2 is a soluble, 14 kDa protein consisting of a disordered N-terminal region, followed by two 
EF-hand domains. The MCFD2-∆N construct is depicted below the wildtype. 
 
To purify the different constructs, the growth medium was separated from the cells by 
centrifugation and the protein isolated from the medium by immobilised metal affinity 
chromatography (IMAC) via the N-terminal His6-tag, followed by size exclusion 
chromatography (SEC). This protocol resulted in pure protein, as judged by SDS-PAGE. 
Both protein constructs consistently eluted as two distinct species from the SEC column and, 
by comparing their elution volumes to a standard curve produced based on a set of proteins  
 
 
Figure 11: Purification of different ERGIC-53 constructs and complex formation with MCFD2-∆N. (a) Size 
exclusion chromatograms of ERGIC-53 4H+L, ERGIC-53 4H and ERGIC-53 3H obtained from the final 
purification step on a Superdex S200 16/60 column (GE Healthcare). The three constructs elute at volumes 
corresponding to a hexameric and a dimeric species, and the isolated CRD is present as a degradation product. 
(b) SEC analysis of dimeric ERGIC-53 4H. Reinjection of the purified dimer leads to the formation of a 
hexameric protein. After incubation of this fraction with MCFD2-∆N, a shift towards a volume corresponding to 
a larger molecular mass is observed, proving the stable formation of the complex. (c) SDS-PAGE analysis of 
hexameric ERGIC-53 4H after complex formation with MCFD2-∆N and SEC. 
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with known molecular weight, the masses of the two species could be calculated to 
approximately 100 kDa and 300 kDa, respectively, corresponding to the theoretical masses of 
ERGIC-53 dimers and hexamers. This was also the case for the ERGIC-53 3H construct 
produced in E. coli (figure 11a). 
To increase the purity of the dimeric ERGIC-53 4H, anion exchange chromatography (IEX) 
was performed and again, two distinct fractions eluted from the IEX column. These were 
later identified by DLS to correspond to monomers and dimers. In contrast, when performing 
the same experiment with hexameric ERGIC-53 4H, no dissociation of the protein was 
observed. 
 
3.4.2 The Oligomerisation of ERGIC-53 
The two ERGIC-53 oligomers were further investigated by SEC, native PAGE and 
glutaraldehyde crosslinking experiments. Both hexameric and dimeric species of ERGIC-53 
4H were re-injected into the SEC column and the resulting elution profiles showed that, while 
the hexamer neither dissociated into smaller oligomers nor formed higher oligomeric species, 
the re-injected dimer eluted at the volumes of both hexamer and dimer, indicating that the 
dimers are competent of forming a stable hexamer (figure 11b).  
 
 
Figure 12: Analyses of the oligomerisation behaviour of ERGIC-53. (a) SEC runs of ERGIC-53 4H alone and 
after incubation with MCFD2 and MCFD2-∆N, respectively, on a Superdex S200 10/300 column (GE 
Healthcare). Neither construct of MCFD2 changes the ratio between dimer and hexamer, indicating no 
consequence of the presence of MCFD2 on the oligomeric state of ERGIC-53 4H. (b) Native PAGE analyses of 
dimeric and hexameric ERGIC-53 4H+L in the presence and absence of the reducing agent DTT. Neither 
species dissociates in the presence of DTT, indicating that the two membrane-proximal cysteine residues are not 
instrumental for keeping oligomeric ERGIC-53 4H+L intact. (c) SDS-PAGE analysis of monomeric, dimeric 
and hexameric ERGIC-53 in the absence of glutaraldehyde, and after 1 and 10 min incubation with 0.025% 
glutaraldehyde, respectively. A clear tendency of the monomeric and dimeric species to assemble into higher 
oligomers is observed. 
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To further elucidate the role of the two cysteine residues present in the membrane-proximal 
linker region, native PAGE analysis of dimeric and hexameric ERGIC-53 4H+L after 
incubation with DTT was performed. The results show no difference in the running behaviour 
between reduced and non-reduced samples of either dimeric or hexameric species (figure 
12b). While this seems to confirm that the cysteines are not instrumental for the stability of 
the oligomers, it cannot be precluded, in particular for the hexamer, that they are in a 
hydrophobic core and well protected from reduction by DTT. 
In order to further strengthen the observation that ERGIC-53 4H+L is assembly-competent, 
crosslinking studies using glutaraldehyde were performed with the monomeric, dimeric and 
hexameric species of ERGIC-53 4H. The results confirm our previous observation, namely 
that the lower oligomeric species are capable of further assembling into higher oligomeric 
species, and also suggest a dispensable role in oligomerisation for the two cysteine residues 
present in the C-terminal linker (figure 12c).  
 
3.4.3 Interaction Studies with MCFD2 
Previous studies have determined the binding affinity between MCFD2 and the ERGIC-53 
CRD to lie in the low-nanomolar region and indicated that this binding is very susceptible to 
mutations in MCFD2. While some mutations disrupt the interface of the complex, others 
render MCFD2 unable to bind Ca2+ and therefore inhibit its folding, which consequently 
inhibits binding to the ERGIC-53 CRD (Nyfeler et al., 2008a; Nishio et al., 2010; Wigren et 
al., 2010; Elmahmoudi et al., 2011). The mutations abolishing the interaction are mostly 
located in the folded EF-hands of MCFD2, and the role of the unfolded N-terminus in this 
interaction has not been investigated thoroughly. Earlier data have shown that the binding 
affinity between native MCFD2 or N-terminally truncated MCFD2-∆N and the ERGIC-53 
CRD lies in the same, low-nanomolar, range (Wigren, 2012), but the oligomerisation domain 
of ERGIC-53 was absent in these studies. We have therefore undertaken different approaches 
to investigate whether the unfolded N-terminus of MCFD2 plays a role in the interaction with 
the full lumenal part of ERGIC-53. Several different potential roles for the unfolded N-
terminus come to mind: firstly, it might be involved in the oligomerisation of ERGIC-53 or 
its stabilisation by providing a link between the monomers, binding to one CRD via its EF 
hands and to the next monomer via the unfolded tail, which would presumably fold upon 
interacting with its partner. Secondly, it might bind to the oligomerisation domain of the same 
or a neighbouring ERGIC-53 molecule or, thirdly, it might be involved in the recruitment of 
cargo glycoproteins to ERGIC-53. To test the first hypothesis, we have performed SEC 
studies with dimeric ERGIC-53 and both native MCFD2 and MCFD2-∆N. After incubating 
dimeric ERGIC-53 4H with each of the two MCFD2 constructs for 1h in the presence of  
5 mM CaCl2, the complexes were analysed by SEC and their elution profiles compared. In 
this experiment, while the complex formation was clearly confirmed by a shift of the elution 
volumes towards a higher molecular mass, no trace of newly formed hexamer was observed 
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for either complex, ruling out the possibility that the unfolded N-terminus of MCFD2 
promotes further oligomerisation of dimeric ERGIC-53 to form hexamers (figure 13). 
 
Figure 13: SPR analyses of the interaction between hexameric ERGIC-53 4H and MCFD2 and MCFD2-∆N, 
respectively. The steady-state response for each injection in relation to the maximum observed response at 
steady-state for the highest concentration is plotted against the MCFD2 concentration. The dissociation constant 
KD, as determined from each constructs concentration at Req = 50%, is 5.6*10-8 M and 1.2*10-8 M, for MCFD2-
∆N and MCFD2, respectively. 
 
The second hypothesis, that the unfolded tail of MCFD2 is binding to the ERGIC-53 
oligomerisation domain, was investigated using SPR. Hexameric ERGIC-53 was 
immobilised on a CM5 chip by amine coupling, and binding assays were performed using 
both native and N-terminally truncated MCFD2 as analytes. The resulting data demonstrated 
a 5-fold increase in the binding affinity of native MCFD2 to hexameric ERGIC-53  
(KD = 1.2*10-8 M), compared to MCFD2-∆N (KD = 5.6*10-8 M), indicating that the N-
terminus is indeed also binding to ERGIC-53. 
To investigate the third hypothesis, which states that MCFD2 is involved in the recruitment 
of cargo molecules to ERGIC-53, we have attempted to recombinantly express several 
constructs of the thus-far identified proteins whose transport from the ER to the ERGIC relies 
on a concerted function of both ERGIC-53 and MCFD2, namely the blood coagulation 
factors FV and FVIII, as well as Mac2-bp, using the BEVS system. Unfortunately though, all 
our efforts to produce these proteins were unsuccessful. 
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3.4.4 Crystallisation of ERGIC-53 
In order to further investigate the structure of the lumenal part of ERGIC-53, crystallisation 
of different constructs and oligomeric species, as well as their complexes with native and N-
terminally truncated MCFD2, was attempted. A total of well over 10 000 small-scale sitting-
drop experiments were set up to identify crystallisation conditions for a number of 
combinations between different ERGIC-53 constructs and oligomeric states in complex with 
both MCFD2 and MCFD2-∆N. The extent and success-rate of these experiments are 
summarised in table 4. Ultimately, two conditions that produced crystals could be identified 
from the screens performed with the complexes between hexameric ERGIC-53 4H and native 
MCFD2, and hexameric ERGIC-53 4H and MCFD2-∆N, respectively. The crystals grown in 
both conditions initially diffracted only poorly, but their size and diffraction quality could be 
enhanced by further optimising the initially identified crystallisation conditions. 
In total, approximately 250 crystals were cryo-protected, flash frozen and tested for 
diffraction at various synchrotron sources.  
 
Table 4: The number of tested crystallisation conditions for each construct.  Figure 14: Crystals of 
ERGIC-53 4H in complex 
with MCFD2. 
 
The first, cone-shaped crystals, obtained from the ERGIC-53 4H hexamer in complex with 
native MCFD2, appeared in a 2:1 mixture of 5.7 mg/ml protein and 0.1 M Tris, pH 7.5 – 
8.25; 11 – 13% (w/v) PEG4000, 0.15 M (NH4)2SO4 after a few days incubation at 4 ºC 
(figure 14) and - after extensive optimisation - grew to approximately 200 µm in length and 
50 µm in width. X-ray diffraction data to a maximum resolution of about 4 Å was recorded at 
the microfocus beamline P14 of the Deutsches Elektronen-Synchrotron (DESY) in Hamburg, 
Germany. The protein crystallised in the space group C2 with the unit cell parameters 
a=275.6 Å, b=49.3 Å, c=305.6 Å, α=γ=90º, β=103.4º. Although the structure of the ERGIC-
53 CRD (Nishio et al., 2010; Wigren et al., 2010) was available, extensive molecular 
replacement searches, making use of differently trimmed models of the CRD in concert with 
different molecular replacement programs, were not successful in solving the structure. Close 
inspection of the individual diffraction images revealed several pathologies in the crystal 
Construct(s) Tested 
conditions 
Crystals obtained 
 
 
ERGIC-53 4H+L hexamer 1440 no 
ERGIC-53 4H hexamer:native MCFD2 1440 yes (1 condition) 
ERGIC-53 4H hexamer:MCFD2-∆N 576 yes (1 condition) 
ERGIC.53 4H dimer:MCFD2-∆N 1728 no 
ERGIC-53 4H dimer 6048 no 
ERGIC-53 3H hexamer 576 no 
ERGIC-53 3H dimer 576 no 
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packing. Smeared spots and possibly a double lattice were observed, in addition to significant 
radiation damage after only a short exposure of the crystal in the X-ray beam. To circumvent 
this problem, data was collected by scanning the crystals helically along their long axis, but 
during data integration and indexing it was revealed that the unit cell was not isomorphous 
along the length of the crystals. The combination of these problems is probably what 
prevented a successful determination of the structure. 
A different approach was undertaken to solve the structure by experimental phasing and for 
this, crystals were soaked with Ta6Br14, a compound previously identified to be suitable for 
isomorphous replacement, especially in the case of large molecules diffracting to low 
resolution (Schneider & Lindqvist, 1994; Banumathi et al., 2003). These crystals were 
however not isomorphous, and diffracted to only ~7 Å resolution, with a very weak 
anomalous signal to ~8.5 Å resolution. The data collection and processing statistics for both 
native and Ta6Br14-derivatised crystals are summarised in table 5. 
After this unsuccessful attempt to determine the structure of hexameric ERGIC-53 4H in 
complex with native MCFD2, a new effort was undertaken and screening for suitable 
crystallisation conditions was resumed. Reasoning that the unfolded N-terminus of MCFD2 
might be unfavourable for homogenous crystal packing, this screening was undertaken using 
the complex of ERGIC-53 4H with the MCFD2-∆N variant at a concentration of 7.5 mg/ml, 
and crystals of a bi-pyramidal shape were obtained from the same condition as previously. 
After observing weak diffraction of these crystals at synchrotron sources, followed by 
optimisation of the crystallisation condition to increase their size and quality, larger crystals 
diffracting to 4 Å resolution could be obtained. It became clear that the protein had once more 
crystallised in the space group C2, but with very different unit cell parameters, namely 
a=379.9 Å, b=218.6 Å, c=219.5 Å, α=γ=90º, β=125.3º. Once more, extensive trials to solve 
the structure by molecular replacement using the available model of the CRD as a whole or 
pruned to its central β-sheet were performed, but were unsuccessful. Later it was discovered 
that these crystals were in fact of a contaminant, namely ferritin from the expression host  
T. ni, and this observation is discussed in more detail in paper IV. Since this revelation it has 
of course to be considered that the crystals produced from the preparations of ERGIC-53 4H 
in complex with native MCFD2 are also of ferritin. Attempts to solve the structure using the 
available structure of ferritin (Hamburger et al., 2005) as a search model have however failed. 
This might not be surprising considering the very different crystal morphology, as one could 
expect ferritin crystals grown in the same condition to be identical. However, due to the low 
quality of these crystals, it has to be considered that the data might have been incorrectly 
processed and it can therefore not be concluded at this time whether the crystalline protein is 
in fact ferritin or ERGIC-53 in complex with MCFD2-∆N. 
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 Native Ta6Br14 derivative 
Data collection   
Beamline PETRA III P14 PETRA III P14 
Wavelength [Å] 0.97628 1.25492 
Space group C2 C2 
Cell axes a, b, c [Å] 275.66, 49.33, 305.42 269.08, 49.76, 302.08 
Cell angles α, β, γ [°] 90.00, 103.38, 90.00 90.00, 100.59, 90.00 
Resolution [Å] 49.55 – 4.00 (4.19 – 4.00) 49.49 – 7.20 (8.04 – 7.20) 
Rmerge 0.24 (1.07) 0.26 (1.02) 
Mean I/σI 6.0 (1.2) 6.6 (1.8) 
Mean CC1/2 0.983 (0.342) 0.99 (0.53) 
Completeness [%] 98.8 (95.8) 94.7 (86.8) 
Multiplicity 3.3 (3.2) 4.3 (4.3) 
Number of reflections 112834 (13963) 24946 (6284) 
Number of unique reflections 34624 (4379) 5778 (1461) 
Wilson B-factor [Å²] 102.9 240.6 
Table 5: Data collection statistics of native crystals of ERGIC-53 4H in complex with MCFD2 and the Ta6Br14-
derived crystals. Statistics for the highest-resolution shell are shown in parentheses. 
 
3.4.5 Small-angle X-ray Scattering 
Concurrently with the crystallographic studies, small-angle X-ray scattering experiments 
were performed to investigate the structure of ERGIC-53 in solution, with the intention to 
complement a possible X-ray crystal structure of monomeric or dimeric ERGIC-53. A low-
resolution solution structure of hexameric ERGIC-53 might have allowed us to build a higher 
resolution model by using the structure of the monomeric or dimeric crystal structure of 
ERGIC-53 as rigid bodies and, by enforcing symmetrical restraints, fit them to the solution 
scattering curve of the hexamer. Since no structure of either monomeric or dimeric  
ERGIC-53 could be obtained, this approach could unfortunately not be undertaken. 
Nevertheless, the SAXS scattering data still allows for some speculation about the structure 
of hexameric ERGIC-53. 
First, SAXS scattering data of dimeric ERGIC-53 4H+L in solution was recorded at beamline 
X33 of the Deutsches Elektronen-Synchrotron (DESY) in Hamburg, Germany (Blanchet et 
al., 2012). The molecular mass of the dimeric protein was estimated to ~100 kDa using 
Guinier analysis implemented by AUTORG (Petoukhov et al., 2007) and comparison of the 
scattering intensity of the extrapolated intensity to zero angle I(0) with a BSA standard, a 
value corresponding well with the theoretical molecular mass of dimeric ERGIC-53 4H+L. 
The maximum intramolecular distance Dmax of the particle was determined to be ~21 nm 
using GNOM (Svergun, 1992) and the paired distance distribution function clearly indicates 
the presence of two domains (figure 15a,b). 
In addition, solution scattering data of the ERGIC-53 4H+L dimer in complex with native 
MCFD2 was recorded. An increased molecular mass of ~120 kDa was determined, while the 
maximum distance Dmax remained approximately the same. The distribution of intramolecular 
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paired distances however differs strongly from that obtained for the dimeric protein alone, as 
it does not show the clear presence of two domains, but rather a shape resembling a rod-like 
structure (figure 15a,c). This observation could be explained by MCFD2 being placed in 
between the two domains, thereby obscuring their separate peaks. 
 
Figure 15: Solution small angle X-ray scattering of ERGIC-53. (a) Solution scattering data of dimeric ERGIC-
53 4H+L alone and in complex with MCFD2 collected at beamline X33 of DESY. The logarithm of the 
scattering intensity is plotted as a function of momentum transfer s=4π sin(Θ)/λ, where Θ is the scattering angle 
and λ is the X-ray wavelength. (b and c) Paired distance-distribution functions of dimeric ERGIC-53 4H+L 
alone and in complex with MCFD2, respectively. (d) Solution scattering data of hexameric ERGIC-53 4H 
collected at beamline P12 of DESY. (e) Paired distance distribution function of hexameric ERGIC-53 4H. Note 
that a comparison of the scattering intensity is invalid as the scattering data was recorded at two different 
beamlines. 
 
By comparing the two shapes obtained from ab initio modelling, we aimed to determine the 
location of the ERGIC-53 CRD within the low-resolution shapes. The difference density 
obtained from the subtraction of the ERGIC-53 model from the complex model could allow 
for the placement of MCFD2, and therefore very likely also identify the approximate position 
of the ERGIC-53 CRD, since the complex structure is well described (Nishio et al., 2010; 
Wigren et al., 2010). To achieve this, low-resolution shapes were computed ab initio based 
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on the scattering data of both the dimeric ERGIC-53 4H+L as well as dimeric ERGIC-53 
4H+L in complex with MCFD2. This analysis was performed using DAMMIF (Franke & 
Svergun, 2009) and a P2-symmetry was imposed, resulting in fit-values as reported by 
DAMMIF of 0.0195 and 0.0158, respectively. One example of a shape of both dimeric 
ERGIC-53 4H+L and its complex with MCFD2 is shown in figure 16. Both models comprise 
an elongated shape with similar dimensions and indeed, additional electron density is 
observed in the centre of each subunit. 
 
As the CRD in complex with MCFD2-∆N has been shown to be monomeric in the absence of 
the oligomerisation domain, it is assumed to be represented by the extremities of the low-
resolution models and was manually placed there using UCSF Chimera (Pettersen et al., 
2004). While the location of the CRD can be identified in these two shapes, the variability of 
other obtained shapes prevents us from drawing sound conclusions from this approach. 
SAXS data of hexameric ERGIC-53 E5 in solution was then recorded at beamline P12 of 
DESY (Blanchet et al., 2015). The molecular weight of the particle is estimated to ~320 kDa, 
again confirming the hexameric nature of ERGIC-53. Furthermore, the paired distance 
distribution function indicates the presence of a multi-domain protein with a Dmax of ~22 nm 
(figure 15d,e) 
Ab initio low-resolution shape determination was performed based on these recordings as 
well, and a P6 symmetry was enforced. The computation resulted in two structurally distinct 
shapes, both of which fit the scattering data similarly well with fit-values as reported by 
DAMMIF of 0.0422 and 0.0446, respectively. While shape 1 resembles a bouquet of flowers 
with elongated stems and a crown, shape 2 can be described as a planar disc with spherical 
elements protruding from its side (figure 16). The volume of the protrusions of both models 
allows for a good fit of one CRD molecule. 
While these models provide some insight into the possible structure of hexameric ERGIC-53, 
they would have to be rigorously validated using other available structural information and, 
while the high-resolution crystal structure of the CRD is available, any sound interpretation 
of the ab initio models is prohibited by the lack of structural data of the oligomerisation 
domain. This would not necessarily be a limiting factor for the interpretation of a monomeric 
model, but since no structural information on the hexameric protein is available, further 
modelling of the oligomerising region of ERGIC-53 becomes cumbersome and unreliable.  
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Figure 16: Low-resolution shapes obtained ab initio based on the scattering data of dimeric ERGIC-53 4H+L in 
complex with MCFD2 and hexameric ERGIC-53 4H. The illustrations on the right are rotated 90º around the 
horizontal axis. 
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3.4.6 Cryo-EM 
To further supplement our X-ray based structural studies of ERGIC-53, attempts to obtain a 
low-resolution structure of the hexameric ERGIC-53 by cryo-electron microscopy were also 
initiated. Initial experiments proved the protein to be suitable for cryo-EM studies and images 
were recorded at a magnification of 60 000x, clearly showing single particles embedded in 
ice (figure 17). To our surprise however, these results were not reproducible with the 
subsequent protein preparations and their vitrification, and cryo-EM studies were therefore 
not continued. 
 
Figure 17: Hexameric ERGIC-53 4H+L embedded in ice, recorded at a magnification of 60 000x using cryo-
EM. The lower panel shows a schematic interpretation of the different particles. 
 
3.4.7 Modelling of the ERGIC-53 Oligomerisation Domain 
In order to facilitate further analysis of the previously described ab initio model of hexameric 
ERGIC-53 derived from the SAXS studies, we aimed to produce a model of the 
oligomerisation domain using the protein structure prediction services QUARK (Xu & 
Zhang, 2012) and Robetta (Raman et al., 2009). Since no structural template of any 
homologous molecule is available, the structures are based on the amino acid sequence only. 
Five of the most structurally diverse examples from the ten models obtained from each 
prediction server are visualised in figure 18.  
The QUARK-models resemble each other in their architecture as they all comprise an 
elongated, ~90 Å long, coiled-coil region encompassing three helices and the most N-
terminal helix most often aligned diagonally to the coiled-coil. In contrast to this, the models 
obtained from Robetta exhibit larger differences in their structures. While the most common 
model displays two stacked coiled-coil regions encompassing two helices, some models 
display a four-helix bundle, and one model is comprised of a five-helix bundle. All models 
are completely α-helical, which is in agreement with data we have obtained from circular 
dichroism experiments (Wigren, 2012). 
A rough estimate of whether these models could resemble the actual structure of the  
ERGIC-53 oligomerisation domain can be performed based on the low-resolution ab initio 
shapes obtained from SAXS experiments. Shape 1 displays an oligomerisation region 
extending over approximately 160 Å, which is longer than any model predicted by either the 
QUARK or Robetta algorithm. In shape 2, the distance ranging from termini of the CRD to 
the centre of the inner disc is approximately 80 Å and would therefore correspond better to 
the length of the models obtained from the QUARK algorithm. This approach has however to 
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be considered very hypothetical, as it is based on two, experimentally unverified, modelled 
systems  
 
 
Figure 18: A selection of models of the ERGIC-53 oligomerisation domain produced by de novo structure 
prediction using the QUARK and Robetta servers. The models are represented as rainbow-coloured cartoons 
with the N-terminus in blue and the C-terminus in red. 
 
One can attempt to use a very different perspective to discuss the role of hexameric  
ERGIC-53 in the cell by applying our current biological and structural knowledge of the 
assembly of the COPII-coat proteins, and of the molecules transported via ERGIC-53 within 
secretory vesicles. 
Recent cryo-EM studies of the COPII-cage revealed the outer layer of the cage, consisting of 
the Sec13-Sec31 complex, to be a cuboctahedron with a diameter of 600 Å, which is 
comparable to the diameter of COPII-coated vesicles observed in vivo (Stagg et al., 2006). 
The arrangement of the Sec13-Sec31 complex seems to be modular and expandable to 
accommodate different cargo sizes. The inner layer, which is recruited to the ER membrane 
by the GTPase Sar1 and interacts directly with the outer layer (Lee et al., 2004), consists of 
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the Sec23-Sec24 complex, and Sec24 has been shown to be responsible for binding to cargo 
proteins via anterograde ER transport motifs (Nishimura & Balch, 1997; Sato & Nakano, 
2002; Wendeler et al., 2007). Recently, it has been suggested that the cargo receptor proteins 
might have a role in directing the structure of the COPII-cage (Gürkan et al., 2006). 
On the lumenal face of the membrane, ERGIC-53 assembles into hexamers. As we have 
demonstrated, the hexameric protein itself has a maximum diameter of ~220 Å, about a third 
of the diameter of the COPII-cage. Only a partial crystal structure of the coagulation factor 
FVIII, which is a 267 kDa protein recognised by ERGIC-53, is available (Shen et al., 2008). 
However, even this available part, which is lacking the major B-region, already has a 
maximum dimension of ~250 Å. It is therefore puzzling to imagine how ERGIC-53 and its 
bound cargo proteins could fit into COPII-coated vesicles of ~500 Å diameter, especially 
when taking into consideration the fact that hexameric ERGIC-53 can potentially bind up to 
six cargo-molecules simultaneously. ERGIC-53 might therefore indeed play a role in the 
expansion of the COPII-cage to allow for the efficient packaging of larger cargo molecules, 
and it can be speculated that the hexameric organisation of the protein translates across the 
membrane and enforces a rearrangement of the COPII-proteins to enforce such an expansion 
(figure 19)  
 
Figure 19: A proposed model for the expansion of COPII-coated vesicles by the incorporation of ERGIC-53. 
Binding of hexameric ERGIC-53 might lead to conformational changes of the Sec23-Sec24 complex via a 
translation of the hexameric arrangement of ERGIC-53 to the cytosolic face of the vesicles. 
 
A major unresolved question concerning the oligomeric ERGIC-53 is why the protein cannot 
effectively transport even smaller cargo proteins in its dimeric state. It does not seem 
plausible that the cell would have an as-yet unknown mechanism to actively hinder dimeric 
ERGIC-53 from being packed into secretory vesicles. There is however evidence 
emphasising a key role for glycoprotein receptors and other proteins interacting with Sec24 in 
the assembly of the coat protein complex (Aridor et al., 1999). Accordingly, failure of 
ERGIC-53 to hexamerise might lead to the aberrant exposure of the cytoplasmic transport 
motif with regards to the location of Sec24 and thereby to an interaction that is too weak for 
both the efficient assembly of the coat-protein complexes and for ERGIC-53 to be efficiently 
packed into vesicles. According to this speculation, ERGIC-53 would actively partake in the 
assembly of the COPII-cage. The binding affinity of Sec24 to the cytosolic di-acidic transport 
motif is, to our best knowledge, yet to be determined. 
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If it is indeed the case that hexameric ERGIC-53 has an advantage over smaller oligomers of 
the protein when it comes to incorporation into COPII-coated vesicles, then this raises the 
possibility that a factor on the lumenal face of the ER membrane extorted some selective 
pressure onto ERGIC-53 to form hexamers. Obvious candidates to enact such a selective 
pressure are the cargo proteins transported by ERGIC-53.  
One interesting case to argue for a selective pressure towards hexameric ERGIC-53 are the 
studies performed in the laboratory of R. Sitia (Anelli et al., 2007, 2015; Cortini & Sitia, 
2010), which showed that the controlled polymerisation and secretion of hexameric IgM 
relies directly on its interaction with hexameric ERGIC-53. Their findings show that a 
conserved N-linked glycan on the C-terminal tailpiece of secretory chains is recognised by 
ERGIC-53, and that the removal of this glycan disturbs the interaction with ERGIC-53 and 
leads to larger polymeric IgM-assemblies. These results suggest a possible function of 
ERGIC-53 as a platform governing the assembly of hexameric IgM. 
With regards to the other cargo molecules of ERGIC-53 that have been thus-far identified, its 
hexameric organisation does not seem to play a role in cargo recognition, as neither α1-
antitrypsin, Cathepsin C and Z, nor Mac2-bp require their presence as oligomers to enact 
their function. 
Additionally, it is intriguing that ERGIC-53 does not seem to be essential for the secretion or 
assembly of the blood coagulation factors. While mutations in ERGIC-53 or MCFD2 lead a 
combined deficiency of the blood coagulation factors V and VIII (F5F8D), patients carrying 
this disease still have blood levels of these proteins at 5-30 % of the normal levels (Nichols et 
al., 1998), suggesting that exit of native FV and FVIII from the ER can also occur via the 
bulk-flow mechanism (Wieland et al., 1987; Thor et al., 2009). 
One could therefore speculate that the primary function of hexameric ERGIC-53 is to assist 
the correct assembly of IgM, whose correct and efficient synthesis is of tremendous 
importance to protect the human body from invasive pathogens, and that other proteins may 
merely have developed the ability to usurp the function of ERGIC-53, in order to themselves 
be transported more efficiently from the ER along the secretory pathway. 
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4 CONCLUSIONS 
Within this thesis project, a number of proteins involved in glycoprotein transport and 
processing in the early secretory pathway have been investigated. X-ray crystallographic 
studies allowed us to determine the structures of both Erv41p and Ktrp4, and small-angle X-
ray scattering experiments performed with ERGIC-53 gave new insights into the shape of this 
protein in its functional, hexameric form. Additional biochemical and biophysical methods 
have been applied to further characterise each protein. 
 
X-ray crystallographic studies of Erv41p led to the first structure of any member of the class 
of ER vesicle proteins, and analyses of the surface properties of the protein's structure 
together with sequence comparisons with its homologues led us to propose a possible site of 
interaction with other proteins. Almost the entirety of one face of the protein is negatively 
charged, and this large surface clearly provides grounds to hypothesise about its potential as a 
protein-protein interaction interface. We also attempted to determine the crystal structure of 
the binding-partner Erv46p, but have unfortunately been unsuccessful. We have however 
been able to show a direct interaction between Erv41p and Erv46p by SPR experiments. As 
the two proteins act in concert when transporting their cargo, further insight into the structure 
of Erv46p and the Erv41p/Erv46p complex is of great interest to completely understand the 
mechanism of protein binding and release by these proteins in the different compartments of 
the early secretory pathway.  
During the course of these studies, Ktr4p was identified as the first protein known to be 
transported by the ER vesicle protein complex, and we have therefore also investigated its 
structure and function. The structure of the apo-protein, as determined by X-ray 
crystallography, shows that it belongs to the GT-A family of glycosyltransferases, and the 
structure of Ktr4p in complex with GDP and Mn2+, combined with its similarity to the 
previously characterised homologue Kre2/Mnt1, led to the hypothesis that it acts as a 
mannosyltransferase. Our biochemical analysis of the catalytic activity confirmed that this is 
indeed the case. The relatively poor activity of the enzyme towards the provided substrates 
however led us to conclude that the experiments were performed with incomplete and/or 
inadequate donor-substrates. Attempts to identify an interaction between Ktr4p and an array 
of complex, branched mammalian glycans were not successful, and the precise substrates of 
the enzyme in the Golgi apparatus therefore remain to be elucidated.  
The protocols we have developed for the recombinant production of Erv41p and Erv46p in 
insect cells, as well as of Ktr4p in E. coli, will allow for further, detailed interaction studies 
between the Erv41p/Erv46p complex or its individual components with Ktr4p. Such studies 
could provide more insight into the mechanism of protein capture within the ER and release 
within the Golgi apparatus, and thereby increase our understanding of the mechanisms 
involved in protein transport between the organelles of the early secretory pathway. 
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Our attempts to determine the structure of Erv46p and the lumenal part of ERGIC-53 led to 
the identification of a common crystallisation contaminant, present after the purification of 
the two recombinantly expressed proteins that were secreted by the insect cells into the 
medium. The expression host T. ni, and specifically its ovarian cell line High Five, is 
becoming more popular as it allows for the production of many eukaryotic proteins whose 
expression fails in the more traditional expression host E. coli. We show that ferritin is a 
contaminant from the High Five strain that is prone to crystallise even in minute amounts, 
and warn about its deceiving presence. 
Our biophysical and biochemical studies performed with different oligomeric states of 
ERGIC-53 shed light on its mechanism of oligomerisation. We show that the oligomerisation 
is independent of disulfide-bond formation, and our results are in agreement with Neve et al., 
but contradict those of Appenzeller et al. and Lahtinen et al. While these three studies have 
been performed in vivo, our in vitro experiments allow us to exclude significant factors that 
may influence the assembly of ERGIC-53. In addition, we show that MCFD2 does not 
promote the oligomerisation of ERGIC-53, but that its unfolded N-terminal tail does interact 
with ERGIC-53 when the oligomerisation domain is present. By studying dimeric and 
hexameric ERGIC-53 with small-angle X-ray scattering we were able to propose a low-
resolution shape for the dimeric protein, and two potential shapes for the hexameric protein. 
The exact structure of the oligomerisation domain is still unknown, and only structural 
information from this domain in its oligomeric state would finally put an end to the 
discussion about the oligomerisation of ERGIC-53. 
 
Overall, the structural, biophysical and biochemical analyses of this work have led to new 
insights into glycoprotein transport and processing in the early secretory pathway, and will 
enable future studies that will hopefully yield a full understanding of each of the individual 
proteins described here, their roles in the cell and their links to disease.  
 
  
  49 
5 ACKNOWLEDGEMENTS 
Very many creative and critical minds have been of immeasurable assistance to me during the 
last few years and I remain deeply grateful for the advice and support I have received. 
First, I would like to thank my supervisor Jodie Guy. You have been my scientific counsellor, 
reviewer, editor and stubborn reminder of rapidly approaching deadlines and your scientific 
expertise has helped me overcome many obstacles. I have learned a lot from you, especially 
in the areas of experimental design and crystallography. Thank you also for giving me the 
freedom to plan and develop the projects independently, but always being there when I 
needed advice. 
I would also like to thank Professor Ylva Lindqvist. Thank you for first accepting me as a 
PhD student and for your further support as my co-supervisor. Your enthusiasm for science in 
general and this project in particular has been truly inspiring and very uplifting in many 
situations. I would also like to thank Professor Gunter Schneider for sharing his expertise and 
regularly giving me helpful advice along the way. I want to thank the three of you for the 
many challenging broad and detailed scientific discussions we have had. Together, you have 
provided an environment of creativity, curiosity and familiarity.  
Edvard, your kindness, patience and persistence from the very first day of my arrival has been 
of great help and our sometimes derailing speculations about this bunch of ER proteins have 
been very fun and insightful. Katja, thank you for your guidance and for sharing so many 
lunches and weekends in the lab. It has been great working with you. Francesca, grazie mille 
for all the help with insect cells and for so many shared synchrotron trips. Your company has 
made the travels much more joyous. I would also like to thank Jenna, during the summer you 
spent in the lab you have helped me a lot, and our co-immunoprecipitation adventures with 
laboratory-grade yeast from hemköp are something to remember. 
I would like to thank everyone who has collaborated with me on the projects of this thesis: 
Magnus, thank you for lending me your knowledge of the sugary side of protein 
crystallography and for being a great colleague and science-nerd. Anne, your support with 
my first steps into the perplexing realm of SAXS was very important for this thesis and I 
thank you for all your help with teaching me how to make sense of the scattering data. Pasi, 
thank you for giving me a glimpse into the world of electron microscopy and all your efforts 
invested into sample preparation and image recording. I would also like to thank everyone at 
the PSF for their most friendly and competent help, which was crucial for the outcome of this 
thesis. Martin, thank you for the maintenance of all the robotic crystallography equipment 
and the sanity of its users, Helena, for advice with construct design and Ida for cloning Ktr4p 
and surprising me with soluble protein only a couple of days later. Thank you Essam for your 
support with SPR studies and your hospitality as my former neighbour.  
I would also like to thank all the previous and present members of the division for the 
fantastic times spent together at work and after: Ömer, thank you for your continued honesty 
and sarcasm and for all the heated conversations. Bernie, for first guiding me towards hjulet 
 50 
and all the analyses of the goings-on in science and the world during the lunch-breaks. Thank 
you especially for your help with developing data-collection strategies, data processing and 
the resulting necessity of troubleshooting. Katharina, your contagious good mood and 
colourful clothing often brought some balance into the office. We should resume the habit of 
sharing long-way-home music. Robert, thank you for all the discussions about the big and 
small questions in science, the lessons on Norse mythology, etymology and nearly forgotten 
cinematic masterpieces. Rajesh, for always being helpful and the many lovely barbecues you 
organised to bring everyone together after work. Jason, for late-night discussions about 
economical superpowers and for being so brave to try to convince me that the Beatles were, 
in fact, not all that important in musical history. Ming-Wei, it has been a pleasure having you 
around. I'm still trying to match your photography skills. Eva-Maria, for your enthusiasm for 
science and organising MBB-pubs. Agata, thank you for the good times here and abroad. A 
polish wedding can never be forgotten! Doreen, for the help with teaching and gatherings in 
the old and the new hood. Atsushi, for help with crystallography and insights into the 
aesthetics of a healthy lunch. Dominic, for deep insights into history and music. I also want to 
thank all the new- and not-so-new-comers in the lab: Brinda, for keeping me awake during 
long synchrotron sessions with Bollywood music. Richard, for constantly trying to hack the 
world and Shoude for your constant smile. Peter, for sharing all your knowledge in such a 
helpful way. Selma, for wreaking havoc in my close proximity. The whole Petzold-gang, for 
opening up a window into the bewildering science of RNA and NMR. Lorenzo and Hampus, 
it has been most fun sharing the office with you and exchanging views on structural biology 
where we could find a common ground. Grazie och Tack! 
I would also like to thank Victoria, Eva and Alessandra for taking care of the to me often 
diffuse administrative side side of research. Thank you for all the help with organising the 
many travels abroad, confusing invoices and reseräkningar. Ahmad, thank you for keeping 
the lab in such a tidy state. You made a big difference.  
Many thanks also to everyone outside the division who has made the last years so enjoyable. 
Juha, for the many climbing and slack-lining sessions and impromptu midnight street-corner 
discussions about all things relevant. Will and Qing, it was most fun working with you on the 
thioreductase. If you ever do work on a less troublesome enzyme, let me know! Rozbeh, 
Michael, Jens, Joe, Lionel, Sergey, Ási, Olle, Fatma, TC, Rosaria, Arwen, Wouter, Ela, 
Devaraj, Jaakko, Shiromi, Emma, Eleonora, Jen, Barbara, Massa, Stef, Isabel and Elisa, thank 
you for the fun times all around Stockholm.  
Christina, Lasse, Henrik, Lovisa och Märta, tack för de fina dagarna på spåren och på lederna 
i fjällen och de många, trevliga middagarna hemma hos er. 
Ein herzliches Dankeschön an meine Familie. Eure Unterstützung in allen meinen 
Entscheidungen und eure moralische Hilfe bei den viel zu seltenen Besuchen daheim oder in 
Stockholm während der letzten Jahre waren unglaublich wichtig. Danke viel, viel mol! 
Maria, du betyder så mycket för mig. Tusen tack för allt! 
  51 
6 REFERENCES 
Akopian, D., Shen, K., Zhang, X., & Shan, S. (2013). Annu. Rev. Biochem. 82, 693–721. 
Anelli, T., Ceppi, S., Bergamelli, L., Cortini, M., Masciarelli, S., Valetti, C., & Sitia, R. 
(2007). EMBO J. 26, 4177–4188. 
Anelli, T., Sannino, S., & Sitia, R. (2015). Free Radic. Biol. Med. 83, 323–330. 
Appenzeller, C., Andersson, H., Kappeler, F., & Hauri, H. P. (1999). Nat. Cell Biol. 1, 330–
334. 
Appenzeller-Herzog, C. & Hauri, H.-P. (2006). J. Cell Sci. 119, 2173–2183. 
Appenzeller-Herzog, C., Roche, A. C., Nufer, O., & Hauri, H. P. (2004). J. Biol. Chem. 279, 
12943–12950. 
Arar, C., Carpentier, V., Le Caer, J. P., Monsigny, M., Legrand, A., & Roche, A. C. (1995). 
J. Biol. Chem. 270, 3551–3553. 
Aridor, M., Bannykh, S. I., Rowe, T., & Balch, W. E. (1999). J. Biol. Chem. 274, 4389–4399. 
Bannykh, S. I., Rowe, T., & Balch, W. E. (1996). J. Cell Biol. 135, 19–35. 
Banumathi, S., Dauter, M., & Dauter, Z. (2003). Acta Crystallogr. Sect. D Biol. Crystallogr. 
59, 492–498. 
Barlowe, C. (2003). Trends Cell Biol. 13, 295–300. 
Belden, W. J. & Barlowe, C. (2001). Science. 294, 1528–1531. 
Blanchet, C. E., Spilotros, A., Schwemmer, F., Graewert, M. A., Kikhney, A., Jeffries, C. M., 
Franke, D., Mark, D., Zengerle, R., Cipriani, F., et al. (2015). J. Appl. Crystallogr. 48, 431–
443. 
Blanchet, C. E., Zozulya, A. V., Kikhney, A. G., Franke, D., Konarev, P. V., Shang, W., 
Klaering, R., Robrahn, B., Hermes, C., Cipriani, F., et al. (2012). J. Appl. Crystallogr. 45, 
489–495. 
Blobel, G. & Dobberstein, B. (1975). J. Cell Biol. 67, 835–851. 
Breuza, L., Halbeisen, R., Jenö, P., Otte, S., Barlowe, C., Hong, W., & Hauri, H. P. (2004). J. 
Biol. Chem. 279, 47242–47253. 
Budnik, A. & Stephens, D. J. (2009). FEBS Lett. 583, 3796–3803. 
Bue, C. A. & Barlowe, C. (2009). J. Biol. Chem. 284, 24049–24060. 
Bue, C. a, Bentivoglio, C. M., & Barlowe, C. (2006). Mol. Biol. Cell. 17, 4780–4789. 
Bygrave, F. L. & Benedetti, A. (1996). Cell Calcium. 19, 547–551. 
Caldwell, S. R., Hill, K. J., & Cooper, A. A. (2001). J. Biol. Chem. 276, 23296–23303. 
 52 
Carrière, V., Piller, V., Legrand, A., Monsigny, M., & Roche, A. C. (1999). Glycobiology. 9, 
995–1002. 
Chavrier, P., Parton, R. G., Hauri, H. P., Simons, K., & Zerial, M. (1990). Cell. 62, 317–329. 
Chen, Y., Hojo, S., Matsumoto, N., & Yamamoto, K. (2013). Glycobiology. 23, 904–916. 
Clapham, D. E. (2007). Cell. 131, 1047–1058. 
Cortini, M. & Sitia, R. (2010). Traffic. 11, 651–659. 
Denks, K., Vogt, A., Sachelaru, I., Petriman, N., Kudva, R., & Koch, H. (2014). Mol. Membr. 
Biol. 31, 58–84. 
Ellgaard, L. & Helenius, A. (2003). Nat. Rev. Mol. Cell Biol. 4, 181–191. 
Elmahmoudi, H., Wigren, E., Laatiri,  a, Jlizi,  a, Elgaaied,  a, Gouider, E., & Lindqvist, Y. 
(2011). Haemophilia. 17, e923–e927. 
Fiedler, K. & Simons, K. (1994). Cell. 77, 625–626. 
Fiedler, K., Veit, M., Stamnes, M. A., & Rothman, J. E. (1996). Science. 273, 1396–1399. 
Fitzgerald, D. J. D. J., Berger, P., Schaffitzel, C., Yamada, K., Richmond, T. J. T. J., & 
Berger, I. (2006). Nat. Methods. 3, 1021–1032. 
Fraldi, A., Zito, E., Annunziata, F., Lombardi, A., Cozzolino, M., Monti, M., Spampanato, 
C., Ballabio, A., Pucci, P., Sitia, R., et al. (2008). Hum. Mol. Genet. 17, 2610–2621. 
Franke, D. & Svergun, D. I. (2009). J. Appl. Crystallogr. 42, 342–346. 
Gauss, R., Kanehara, K., Carvalho, P., Ng, D. T. W., & Aebi, M. (2011). Mol. Cell. 42, 782–
793. 
Gavel, Y. & von Heijne, G. (1990). Protein Eng. 3, 433–442. 
Grinna, L. S. & Robbins, P. W. (1980). J. Biol. Chem. 255, 2255–2258. 
Gürkan, C., Stagg, S. M., Lapointe, P., & Balch, W. E. (2006). Nat. Rev. Mol. Cell Biol. 7, 
727–738. 
Guy, J. E., Wigren, E., Svärd, M., Härd, T., & Lindqvist, Y. (2008). J. Mol. Biol. 381, 941–
955. 
Hamburger, A. E., West, A. P., Hamburger, Z. A., Hamburger, P., & Bjorkman, P. J. (2005). 
J. Mol. Biol. 349, 558–569. 
Hampton, R. Y. & Sommer, T. (2012). Curr. Opin. Cell Biol. 24, 460–466. 
Helenius, A., Trombetta, E. S., Hebert, D. N., & Simons, J. F. (1997). Trends Cell Biol. 7, 
193–200. 
Hill, K., Boone, C., Goebl, M., Puccia, R., Sdicu, A. M., & Bussey, H. (1992). Genetics. 130, 
273–283. 
  53 
Itin, C., Roche,  a C., Monsigny, M., & Hauri, H. P. (1996). Mol. Biol. Cell. 7, 483–493. 
Jackson, M. R., Nilsson, T., & Peterson, P. A. (1990). EMBO J. 9, 3153–3162. 
Jensen, D. & Schekman, R. (2011). J. Cell Sci. 124, 1–4. 
Jigami, Y. & Odani, T. (1999). Biochim. Biophys. Acta - Gen. Subj. 1426, 335–345. 
Kanehara, K., Kawaguchi, S., & Ng, D. T. W. (2007). Semin. Cell Dev. Biol. 18, 743–750. 
Klumperman, J., Schweizer,  a, Clausen, H., Tang, B. L., Hong, W., Oorschot, V., & Hauri, 
H. P. (1998). J. Cell Sci. 111 ( Pt 2, 3411–3425. 
Kondylis, V., Pizette, S., & Rabouille, C. (2009). Semin. Cell Dev. Biol. 20, 817–827. 
Krammer, F., Schinko, T., Palmberger, D., Tauer, C., Messner, P., & Grabherr, R. (2010). 
Mol. Biotechnol. 45, 226–234. 
Kwok, S. C. M., Liu, X., Mangel, P., & Daskal, I. (2006). DNA Cell Biol. 25, 523–529. 
Lahtinen, U., Dahllöf, B., & Saraste, J. (1992). J. Cell Sci. 103 ( Pt 2, 321–333. 
Lahtinen, U., Svensson, K., & Pettersson, R. F. (1999). Eur. J. Biochem. 260, 392–397. 
Lee, M. C. S., Miller, E. A., Goldberg, J., Orci, L., & Schekman, R. (2004). Annu. Rev. Cell 
Dev. Biol. 20, 87–123. 
Lievens, P. M. J., De Servi, B., Garofalo, S., Lunstrum, G. P., Horton, W. A., & Liboi, E. 
(2008). Int. J. Biochem. Cell Biol. 40, 2649–2659. 
Lin, Q.-H., Zhang, K.-D., Duan, H.-X., Liu, M.-X., Wei, W.-L., & Cao, Y. (2015). Cancer 
Sci. 106, 1463-73. 
Li, S. (2010). Cell Res. 20, 1148–1157. 
Lobsanov, Y. D., Romero, P. a., Sleno, B., Yu, B., Yip, P., Herscovics, A., & Howell, P. L. 
(2004). J. Biol. Chem. 279, 17921–17931. 
Locke, M. & Leung, H. (1984). Tissue Cell. 16, 739–766. 
Lussier, M., Sdicu, A. M., Bussereau, F., Jacquet, M., & Bussey, H. (1997). J. Biol. Chem. 
272, 15527–15531. 
Lussier, M., Sdicu, A. M., & Bussey, H. (1999). Biochim. Biophys. Acta - Gen. Subj. 1426, 
323–334. 
Lussier, M., Sdicu, A. M., Camirand, A., & Bussey, H. (1996). J. Biol. Chem. 271, 11001–
11008. 
Margulis, N. G., Wilson, J. D., Bentivoglio, C. M., Dhungel, N., Gitler, A. D., & Barlowe, C. 
(2015). Traffic. 1, 1–20. 
Matsuoka, K., Orci, L., Amherdt, M., Bednarek, S. Y., Hamamoto, S., Schekman, R., & 
Yeung, T. (1998). Cell. 93, 263–275. 
 54 
Mattioli, L., Anelli, T., Fagioli, C., Tacchetti, C., Sitia, R., & Valetti, C. (2006). J. Cell Sci. 
119, 2532–2541. 
Mohorko, E., Glockshuber, R., & Aebi, M. (2011). J. Inherit. Metab. Dis. 34, 869–878. 
Morais, V. A., Brito, C., Pijak, D. S., Crystal, A. S., Fortna, R. R., Li, T., Wong, P. C., Doms, 
R. W., & Costa, J. (2006). Biochim. Biophys. Acta. 1762, 802–810. 
Muñiz, M., Nuoffer, C., Hauri, H. P., & Riezman, H. (2000). J. Cell Biol. 148, 925–930. 
Munro, S. & Pelham, H. R. (1987). Cell. 48, 899–907. 
Nakanishi, H., Suda, Y., & Neiman, A. M. (2007). J. Cell Sci. 120, 908–916. 
Nakatsukasa, K. & Brodsky, J. L. (2008). Traffic. 9, 861–870. 
Neve, E. P. a, Lahtinen, U., & Pettersson, R. F. (2005). J. Mol. Biol. 354, 556–568. 
Nichol, H., Law, J. H., & Winzerling, J. J. (2002). Annu. Rev. Entomol. 47, 535–559. 
Nichols, W. C., Seligsohn, U., Zivelin, A., Terry, V. H., Hertel, C. E., Wheatley, M. a., 
Moussalli, M. J., Hauri, H. P., Ciavarella, N., Kaufman, R. J., et al. (1998). Cell. 93, 61–70. 
Nishimura, N. & Balch, W. E. (1997). Science. 277, 556–558. 
Nishio, M., Kamiya, Y., Mizushima, T., Wakatsuki, S., Sasakawa, H., Yamamoto, K., 
Uchiyama, S., Noda, M., McKay, A. R., Fukui, K., et al. (2010). Proc. Natl. Acad. Sci. U. S. 
A. 107, 4034–4039. 
Noda, Y., Hara, T., Ishii, M., & Yoda, K. (2014). Biol. Open. 3, 209–224. 
Nufer, O., Kappeler, F., Guldbrandsen, S., & Hauri, H.-P. (2003). J. Cell Sci. 116, 4429–
4440. 
Nyfeler, B., Kamiya, Y., Boehlen, F., Yamamoto, K., Kato, K., de Moerloose, P., Hauri, H.-
P., & Neerman-Arbez, M. (2008a). Blood. 111, 1299–1301. 
Nyfeler, B., Reiterer, V., Wendeler, M. W., Stefan, E., Zhang, B., Michnick, S. W., & Hauri, 
H.-P. (2008b). J. Cell Biol. 180, 705–712. 
Nyfeler, B., Zhang, B., Ginsburg, D., Kaufman, R. J., & Hauri, H. P. (2006). Traffic. 7, 1473–
1481. 
Okamoto, M., Kurokawa, K., Matsuura-Tokita, K., Saito, C., Hirata, R., & Nakano,  a. 
(2012). J. Cell Sci. 125, 3412–3420. 
Otte, S. & Barlowe, C. (2002). EMBO J. 21, 6095–6104. 
Otte, S. & Barlowe, C. (2004). Nat. Cell Biol. 6, 1189–1194. 
Otte, S., Belden, W. J., Heidtman, M., Liu, J., Jensen, O. N., & Barlowe, C. (2001). J. Cell 
Biol. 153, 503–517. 
Parodi, A. J. (2000). Annu. Rev. Biochem. 69, 69–93. 
  55 
Paroutis, P., Touret, N., & Grinstein, S. (2004). Physiology (Bethesda). 19, 207–215. 
Patterson, G. H., Hirschberg, K., Polishchuk, R. S., Gerlich, D., Phair, R. D., & Lippincott-
Schwartz, J. (2008). Cell. 133, 1055–1067. 
Pelham, H. R., Hardwick, K. G., & Lewis, M. J. (1988). EMBO J. 7, 1757–1762. 
Pelham, H. R. & Rothman, J. E. (2000). Cell. 102, 713–719. 
Petoukhov, M. V, Konarev, P. V, Kikhney, A. G., & Svergun, D. I. (2007). J. Appl. 
Crystallogr. 40, s223–s228. 
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., 
& Ferrin, T. E. (2004). J. Comput. Chem. 25, 1605–1612. 
Pezzati, R., Bossi, M., Podini, P., Meldolesi, J., & Grohovaz, F. (1997). Mol. Biol. Cell. 8, 
1501–1512. 
Pimpaneau, V., Midoux, P., Monsigny, M., & Roche, A. C. (1991). Carbohydr. Res. 213, 95–
108. 
Porter, K. R., Claude, A., & Fullam, E. F. (1945). J. Exp. Med. 81, 233–246. 
Powers, J. & Barlowe, C. (2002). Mol Biol Cell. 13, 880–891. 
Raman, S., Vernon, R., Thompson, J., Tyka, M., Sadreyev, R., Pei, J., Kim, D., Kellogg, E., 
DiMaio, F., Lange, O., et al. (2009). Proteins. 77 Suppl 9, 89–99. 
Sánchez-Rodríguez, A., Tytgat, H. L. P., Winderickx, J., Vanderleyden, J., Lebeer, S., & 
Marchal, K. (2014). BMC Genomics. 15, 349. 
Saraste, J. & Kuismanen, E. (1984). Cell. 38, 535–549. 
Saraste, J., Palade, G., & Farquhar, M. (1987). J. Cell Biol. 105, 2021–2029. 
Satoh, T., Cowieson, N. P., Hakamata, W., Ideo, H., Fukushima, K., Kurihara, M., Kato, R., 
Yamashita, K., & Wakatsuki, S. (2007). J. Biol. Chem. 282, 28246. 
Satoh, T., Suzuki, K., Yamaguchi, T., & Kato, K. (2014). PLoS One. 9, e87963. 
Sato, K. & Nakano, A. (2002). Mol. Biol. Cell. 13, 2518–2532. 
Sauvageau, E., Rochdi, M. D., Oueslati, M., Hamdan, F. F., Percherancier, Y., Simpson, J. 
C., Pepperkok, R., & Bouvier, M. (2014). Traffic. 15, 383–400. 
Schimmöller, F., Singer-Krüger, B., Schröder, S., Krüger, U., Barlowe, C., & Riezman, H. 
(1995). EMBO J. 14, 1329–1339. 
Schneider, G. & Lindqvist, Y. (1994). Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 186–
191. 
Schweizer, A., Fransen, J., Bächi, T., Ginsel, L., & Hauri, H. (1988). J. Cell Biol. 107, 1643–
1653. 
 56 
Shen, B. W., Spiegel, P. C., Chang, C., Huh, J., Lee, J., Kim, J., Kim, Y., & Stoddard, B. L. 
(2008). Blood. 111, 1240–1247. 
Shibuya, A., Margulis, N., Christiano, R., Walther, T. C., & Barlowe, C. (2015). J. Cell Biol. 
208, 197–209. 
Springer, S., Chen, E., Duden, R., Marzioch, M., Rowley, A., Hamamoto, S., Merchant, S., & 
Schekman, R. (2000). Proc. Natl. Acad. Sci. U. S. A. 97, 4034–4039. 
Stagg, S. M., Gürkan, C., Fowler, D. M., LaPointe, P., Foss, T. R., Potter, C. S., Carragher, 
B., & Balch, W. E. (2006). Nature. 439, 234–238. 
Stamnes, M. A., Craighead, M. W., Hoe, M. H., Lampen, N., Geromanos, S., Tempst, P., & 
Rothman, J. E. (1995). Proc. Natl. Acad. Sci. 92, 8011–8015. 
Stanley, P. (2011). Cold Spring Harb. Perspect. Biol. 3, 1–13. 
Van den Steen, P., Rudd, P. M., Dwek, R. A., & Opdenakker, G. (1998). Crit. Rev. Biochem. 
Mol. Biol. 33, 151–208. 
Stolz, A. & Wolf, D. H. (2010). Biochim. Biophys. Acta. 1803, 694–705. 
Südhof, T. C. & Rothman, J. E. (2009). Science. 323, 474–477. 
Svergun, D. I. (1992). J. Appl. Crystallogr. 25, 495–503. 
Takida, S., Maeda, Y., & Kinoshita, T. (2008). Biochem. J. 409, 555–562. 
Thor, F., Gautschi, M., Geiger, R., & Helenius, A. (2009). Traffic. 10, 1819–1830. 
Tisdale, E. J., Plutner, H., Matteson, J., & Balch, W. E. (1997). J. Cell Biol. 137, 581–593. 
Tremblay, L. O. & Herscovics, A. (1999). Glycobiology. 9, 1073–1078. 
Unligil, U. M. & Rini, J. M. (2000). Curr. Opin. Struct. Biol. 10, 510–517. 
Vainio, P., Mpindi, J.-P. P., Kohonen, P., Fey, V., Mirtti, T., Alanen, K. a., Perälä, M., 
Kallioniemi, O., & Iljin, K. (2012). PLoS One. 7, e39801. 
Velloso, L. M., Svensson, K., Pettersson, R. F., & Lindqvist, Y. (2003). J. Mol. Biol. 334, 
845–851. 
Velloso, L. M., Svensson, K., Schneider, G., Pettersson, R. F., & Lindqvist, Y. (2002). J. 
Biol. Chem. 277, 15979–15984. 
Vollenweider, F., Kappeler, F., Itin, C., & Hauri, H. P. (1998). J. Cell Biol. 142, 377–389. 
Wang, J.-J., Qiu, L., Cai, Q., Ying, S.-H., & Feng, M.-G. (2014). Fungal Genet. Biol. 70, 1–
10. 
Wang, X. H., Nakayama, K. I., Shimma, Y. I., Tanaka, A., & Jigami, Y. (1997). J. Biol. 
Chem. 272, 18117–18124. 
Welsh, L. M., Tong, A. H. Y., Boone, C., Jensen, O. N., & Otte, S. (2006). J. Cell Sci. 119, 
4730–4740. 
  57 
Wendeler, M. W., Paccaud, J.-P., & Hauri, H.-P. (2007). EMBO Rep. 8, 258–264. 
Wieland, F. T., Gleason, M. L., Serafini, T. A., & Rothman, J. E. (1987). Cell. 50, 289–300. 
Wigren, E. (2012). Structural studies of the ERGIC-53/MCFD2 glycoprotein transport 
receptor complex. 
Wigren, E., Bourhis, J. M., Kursula, I., Guy, J. E., & Lindqvist, Y. (2010). FEBS Lett. 584, 
878–882. 
Wilde, M., Klausberger, M., Palmberger, D., Ernst, W., & Grabherr, R. (2014). Biotechnol. 
Lett. 36, 743–749. 
Xu, D. & Zhang, Y. (2012). Proteins. 80, 1715–1735. 
Zhang, B., Cunningham, M. a, Nichols, W. C., Bernat, J. a, Seligsohn, U., Pipe, S. W., 
McVey, J. H., Schulte-Overberg, U., de Bosch, N. B., Ruiz-Saez, A., et al. (2003). Nat. 
Genet. 34, 220–225. 
Zhang, B., McGee, B., Yamaoka, J. S., Guglielmone, H., Downes, K. A., Minoldo, S., 
Jarchum, G., Peyvandi, F., De Bosch, N. B., Ruiz-Saez, A., et al. (2006). Blood. 107, 1903–
1907. 
Zheng, C., Liu, H. H., Yuan, S., Zhou, J., & Zhang, B. (2010). Blood. 116, 5698–5706. 
Zheng, C., Page, R. C., Das, V., Nix, J. C., Wigren, E., Misra, S., & Zhang, B. (2013). J. Biol. 
Chem. 288, 20499–20509. 
 
